

fip annual report '08/'09 **change**





Annual Report 2008-2009

Federation Internationale Pharmaceutique (FIP)

annual report index

Special Focus 2020 Vision	7
Message from the President	13
Year in Review	19
Congress Report	27
FIP-WHO Collaboration Report	33
Regional Pharmaceutical Forums	43
Intro	
Americas	
EuroPharm	
Africa	
SEAR	
EMRO	
Western Pacific	
Member Organisations	57
Board of Pharmaceutical Science and Special Interest Groups	63

Board of Pharmaceutical Practice and Sections	75
Intro	
Academic	
Administrative	
Clinical Biology	
Community	
Hospital	
Industrial	
Lab and Med Control	
Military and Emergency	
Pharmacy Information	
FIP Young Pharmacists Group	93
Finances	99
Realising the vision through FIP Members	105
Colophon	129

special focus 2020 vision

*At the 2008 FIP Congress in Basel, Switzerland, the FIP Council comprised of voting Member Organisations unanimously voted to adopt a new Mission, Vision and Strategic Plan for the Federation. This was a monumental move for a Federation invested in almost 100 years of history, one that placed FIP firmly within the context of global changes in healthcare and medicines use; and one that put FIP's clear Vision in the spotlight for all Members, Partners, Stakeholders and observers: **whenever and wherever medicines are spoken about on a global level, FIP is at the table.***

This new Vision was not arrived upon lightly, nor were the accompanying and supportive Mission and Strategic Plan. All were the result of a comprehensive process that began almost two years ago; a process that began in a brainstorming session among FIP Staff, ExCo and Member Organisation Representatives. It grew in momentum and shape into what is now a full seated plan we have adopted as 2020 Vision.

From the beginning, the emergent Plan encouraged and incorporated input from organs that contribute to the operation of the Federation as well as those which

influence our work and decisions, such as patients. Discussions and deliberations were held between the President and General Secretary/CEO and within the ExCo and eventually through the Bureau, producing through deliberations and discussions a document which identifies and spells out the Vision, Mission and Strategic Directions for FIP.

The process outlined depended on the input and interaction of many different players in the FIP world, including a thorough analysis of external factors affecting global healthcare and internal factors governing the running of the Federation. It was our intention that the process result in a plan that clearly locates FIP on the global stage of medicines and healthcare, keeping patients in the centre of our focus, through the engagement of all stakeholders and a consideration of all factors.

In recognition of the fact that as of late the profession has seen a profound shift in focus from products to patients, FIP's mission has been transformed to best suit the accomplishment of the Vision. The pharmacist has become a direct provider of services, from primary prevention of disease to therapeutic monitoring, providing accurate and relevant information. The modern pharmacist is a provider of patient care. The pharmacist's role – to ensure that the patient's drug therapy is appropriately indicated, the most effective available, the safest possible, and the most convenient – should now be recognised. Pharmacists are currently key players in promoting wellness, preventing disease and contributing to disease management, in close collaboration with other healthcare professionals, so that patients enjoy the best possible results from their medicines.



As such, FIP has adopted a renewed Mission: *to improve global health by advancing pharmacy practice and science to enable better discovery, development, access to and safe use of appropriate, cost-effective, quality medicines worldwide.*

These are not meagre goals and cannot be accomplished without set Strategies and key Tactical Approaches. Encompassing the advancement of pharmacy science, practice and education through increased visibility, communication, partnerships and supporting revenues, FIP's newly identified Strategic Objectives and Tactical Approaches are steering the Federation on the right path to fulfilling the Mission and in turn realising the 2020 Vision.

For the FIP Member Organisations to accept and move forward under new directives was, in its purest form, a choice – a choice for change. And thus the stage was set for this annual report, which has been built upon this choice and exemplifies FIP's dedication to connecting the evolving philosophies of the Federation to goals and resulting tangible outcomes as seen through our Members, and in turn through their Members, and eventually upon our most important Stakeholders: the patients.

The images you see within the pages of this annual report have all been submitted by FIP Member Organisations. Selected Member Organisations from all regions of the world were sent special, analogue, Lomography cameras, which create a type of specially coloured photograph like you see within. The film was collected and developed in The Netherlands and the resulting photographs are remarkable snapshots into the lives of pharmacists and pharmaceutical scientists from all over the world. These are the individuals who are served by FIP through our Member Organisations; these are the individuals who serve the patients that benefit from our unyielding dedication to improve healthcare for all on a global level.

We thank all Member Organisations who participated in this special project, as well as Lomography Cameras for their generous donation to our cause.

FIP's new Vision, Mission and Strategic Plan are young – less than a year old. Yet they hold with them the wisdom of 100 years of history in the perspective of constantly changing global healthcare scenarios and a continuously evolving profession.

The Leaders, Officers, Members and Stakeholders of FIP have energetically accepted and dedicated themselves to 2020 Vision, FIP's Mission, Vision and Strategic Plan. It is our intention to bring news in coming years of its successes as it matures in our global environment.



leadership

message from the president

Dr Kamal K Midha, FIP President

Dear Reader,

As the President of the International Pharmaceutical Federation, it is my pleasure to present to you the 2008-2009 Annual Report

We hope to illustrate in both design and in content that “change” is the theme of this annual report. The 2008-2009 year has been one of just that – “Change” – for FIP; some subtle, some substantial, but all filled with such potential that one cannot help but feel a sense of renewed enthusiasm for pharmacy, the pharmaceutical sciences and FIP’s growing presence in the evolution of healthcare around the world.

A defining moment of the change for the Federation came at the 68th FIP Congress in Basel, Switzerland in September, 2008. It was in Basel that the FIP Council, comprised of our 120 Member Organisations, unanimously accepted the newly developed Vision, Mission and Strategic Plan. Prophetically entitled 2020 Vision – FIP’s Vision, Mission and Strategic Plan, the document outlines the aspired goal of the Federation for

the coming years: **Wherever and whenever decision makers discuss any aspect of medicines on a global level, FIP is at the table.** Its acceptance firmly places FIP leaders and members on the same solid foundation for advancement and endows them with the tools for its achievement.

Shortly after this momentous decision in September 2008, a meeting took place in October 2008 in Amsterdam, The Netherlands bringing together influential stakeholders within and related to the pharmaceutical sciences. Using 2020 as a target point, their goal was to discuss, determine and hypothesise the current and future state of the pharmaceutical sciences on a world-wide level. The result of this meeting was a report entitled *The Pharmaceutical Sciences in 2020* and is an invaluable complement to the work put forward in FIP's 2020 Vision.

It is from 2020 Vision where this annual report finds its roots. As our Member Organisations were of pinnacle importance in enabling FIP to move forward with the ambitious goals set out for the Federation, we felt it of utmost importance to further involve them in the ongoing activities and communication of the Federation. As such, the photographs and quotes you see within the 2008-2009 FIP Annual Report have all come from FIP Member Organisations, submitted from all over the world.

The goal was to connect FIP to real-life examples of pharmacy practice and science, through the eyes, ears and thoughts of our Member Organisations. The remarkable photos we received clearly show this extraordinary link, and we thank all contributing Members for their time and effort in this project.

True to our new vision and mission, FIP was quick to move from its adoption of the Strategic Plan to action, increasing communication, visibility, partnerships and support. Already in place was the new FIP website, launched just prior to the Congress in Basel, an imperative start to a new era of increased interaction, feedback and communication for the Federation. The website continues to grow and evolve with the ultimate goal of being an extensive forum of information and networking for current and potential FIP Members.

The Basel Congress itself created the perfect circumstances for the meeting of minds to focus on key initiatives that support the growth of the Federation and fulfilment of the Mission and vision. This is evident in the success of the Global Hospital Pharmacy Conference, which brought together hundreds of hospital pharmacists from around the world to develop The Basel Statements dedicated areas of focus and growth for this sector. As the year went on, FIP dedicated much time and effort into several new Statements of Policy and Reference documents – key tools that provide Member Organisations with the support and encouragement to make tangible change in their countries and regions. The relevant and timely issues of Quality Assurance for Pharmacy Education, Collaborative Pharmacy Practice and, very importantly, Good Pharmacy Practice have all been deliberated, researched and developed; FIP intends to publish the official papers throughout 2009.

Lending to the successful changes of this year are the expanding FIP partnerships. We continue to increase our inter-activity with the World Health Organization, gaining ground in positioning ourselves as an invaluable partner in improving the quality, access and rational use and delivery of medicines on a global level – this to the end of better patient outcomes and improved health of communities. Our ties to the World Health Professions Alliance continue to generate ground-breaking initiatives as demonstrated with the first World Health Professions

Conference on Regulation held in conjunction with the World Health Assembly in 2008.

As you will continue to read within the pages that follow, the initiatives and endeavours that FIP continually envisions and implements through the work of our Boards, Pharmacy Practice Sections and Scientific Special Interest Groups are making great strides in advancing and advocating for the role of the pharmacist and pharmaceutical scientist in the development of need based medicines and the provision of proper health-care. As a result, we are steadily realising our potential to the acknowledgement of our global partners.

In essence, we are taking our place at the table.



expertise

year in review

Founded in 1912, the International Pharmaceutical Federation (FIP) is the global federation of national associations of pharmacists and pharmaceutical scientists in official relations with the World Health Organization (WHO). Through its 122 Member Organisations and 4000 Individual Members, FIP represents and serves almost two million practitioners and scientists around the world.

Throughout its almost 100 year history, FIP's priorities have expanded both literally and figuratively to meet the needs and expectations of the profession in expanding healthcare services and integrating emerging scientific developments. Changes in pharmacy and the emergence of Pharmacy Practice as a cornerstone of the profession have lead FIP to become globally visible for its advocacy on behalf of the role of the pharmacist in the provision of healthcare, while still maintaining its grounding in the pharmaceutical sciences.

In parallel, the membership of FIP has evolved to become the most extensive global pharmacy and pharmaceutical sciences network. This network is continuing to expand its influence through partnerships with some of the world's leading healthcare, educational and scientific institutions.

FIP Bureau: The Board of FIP

The board of FIP because of historical reasons is called the Bureau and consists of 15 elected officers:

- President
- Immediate Past President
- Chair of the Board of Pharmaceutical Sciences
- Chair of the Board of Pharmaceutical Practice
- Scientific Secretary
- Professional Secretary
- 9 Vice Presidents

Five of the Vice Presidents are appointed by Council from amongst those proposed by the Bureau (who, in turn, receive proposals for candidates from the Member Organisations). Two Vice Presidents are appointed by Council from amongst those proposed by the Board of Pharmaceutical Sciences and two Vice Presidents are appointed by Council from amongst those proposed by the Board of Pharmaceutical Practice.

Executive Committee

The Executive Committee is composed of the President, the Scientific Secretary and the Professional Secretary.

The Executive Committee prepares, proposes and co-ordinates all the activities of FIP, and refers these matters to the Bureau.

The General Secretary is the Chief Executive Officer and is responsible for, amongst others, all staff matters and the management of financial affairs. The General Secretary is an ex officio member of all organs of FIP, but without voting rights.

The Bureau met on three occasions during the year in review. The first meeting was held on 26 and 27 January in The Hague, The Netherlands. The second Bureau meeting took place in Geneva, Switzerland on 16 May. The third meeting was held on 29 August in Basel, Switzerland, prior to the FIP Congress.

Bureau Members before September 2008

President*

Prof. K.K. Midha, Canada

General Secretary*

Mr A.J.M. Hoek, The Netherlands

Professional Secretary*

Prof. H.R. Manasse Jr., United States

Scientific Secretary*

Dr V. P. Shah, United States

Immediate Past President*

Mr J. Parrot, France

Chairman of the Board of Pharmaceutical Sciences

Prof. D.J.A. Crommelin, The Netherlands

Chairman of the Board of Pharmaceutical Practice

Prof. P.J. Schneider, United States

Vice Presidents:

Mr J.A. Bell, Australia
Dr M. Buchmann, Switzerland
Ms B. Frøkjær, Denmark
Prof. M. Hashida, Japan
Dr M.L. Rocci, United States
Prof. M. Rowland, United Kingdom
Mr P.D. Sheth, India
Mrs L.J. Stone, United Kingdom
Dr Th. F. J. Tromp, The Netherlands

Bureau Members after September 2008**President***

Prof. K.K. Midha, Canada

General Secretary*

Mr A.J.M. Hoek, The Netherlands

Professional Secretary*

Prof. H.R. Manasse Jr., United States

Scientific Secretary*

Dr V. P. Shah, United States

Immediate Past President*

Mr J. Parrot, France

Chairman of the Board of Pharmaceutical Sciences

Prof. M. Hashida, Japan

Chairman of the Board of Pharmaceutical Practice

Prof. P.J. Schneider, United States

Vice Presidents:

Mr J.A. Bell, Australia
Mr T. Björk, Sweden
Dr C. Peña, Spain
Dr M.L. Rocci, United States
Mr P.D. Sheth, India
Mrs L.J. Stone, United Kingdom
Dr Th. F. J. Tromp, The Netherlands
Prof. G.T. Tucker, United Kingdom
Dr Régis Vaillancourt, Canada

Executive Committee

The Executive Committee met on seven occasions in 2008: 24 January and 30 March in The Hague, The Netherlands; 10 and 15 May in Geneva, Switzerland; 18 and 19 July in Chicago Illinois, USA; 28 August in Basel, Switzerland; 6 and 7 October in The Hague, The Netherlands and 12 and 13 December in Bethesda, Maryland, USA.

Council

The Council, governing body of FIP, met on 30 August and 4 September 2008 in Basel, Switzerland. Highlights of this meeting included:

The acceptance of four new Member Organisations:

1. Pharmacists Order of Albania
2. Pharmaceutical Society of China Taiwan (This organisation was already a Member Organisation and only requested to change their status to Predominantly Scientific)
3. European Federation for Pharmaceutical Sciences (EUFEPS) (EUFEPS has been an Observer Organisation for many years and has become a full Member Organisation).
4. Georgian Pharmacists' Federation: the President requested the Council to approve this organisation in principle and to give the responsibility to the Bureau to ask for a mandate to the Bureau to accept this organisation, as contact has not been possible after the Bureau received their application. I am not sure if we need to include this organisation, as we have not heard from them since.
5. Association des pharmaciens hospitaliers du Luxembourg, a.s.b.l.

*The organisations marked with an * requested to be admitted as Predominantly Scientific Member Organisations (PSMO).*

* Members of the Executive Committee

The cancellation of two Member Organisations:

- Bulgarian Scientific Pharmaceutical Association
- Colegio Nacional de Químicos Farmaceuticos
BiólogosMéxico

Bureau Elections:

Ratification of the Chairman of the Board of Pharmaceutical Sciences (BPS) chosen from amongst the members of the Board of Pharmaceutical Sciences:

- Prof. Mitsuru Hashida (Japan)

Ratification of a Vice President proposed by the Board of Pharmaceutical Sciences (BPS):

- Prof. Geoffrey Tucker (UK)

Ratification of a Vice President proposed by the Board of Pharmaceutical Practice (BPP):

- Dr Régis Vaillancourt (Canada)

Election of two Vice Presidents through the Bureau:

- Mr Thony H. Björk (Sweden)
- Dr Carmen Peña (Spain)

Working Group on Public Policy

The Working Group consisted of:

Lowell Anderson, *Convenor*

John Gans

Henri Lepage

Carmen Peña

Niels Kristensen

Chui Wai Keung

The Working Group on Public Policy met twice during 2008. The first meeting was held on 2 September in Basel, Switzerland to review Statements of Professional Standards and Policy, which were later submitted for adoption during the 2008 Council meeting. The following documents were presented and adopted by Council on 4 September:

1. FIP Statement of Policy on Control of Antimicrobial Medicines Resistance (AMR)
2. FIP Statement of Policy on Medicines Information for Patients
3. FIP Statement of Policy on the Quality of Medicines used for Children

The second meeting was held from 31 October and 1 November in Madrid, Spain, and was chaired by the Convenor.

Awards 2008:

In previous years the FIP Foundation for Education and Research recognised outstanding achievements in the fields of Pharmaceutical Practice or the Pharmaceutical Sciences by granting Awards. At the Bureau Meeting of 3 September 2004, it was decided that as of 2005 these Foundation awards would become FIP Awards.

Types and Hierarchy of FIP Awards

General	Practice	Science
Honorary President		
	André Bédard Award	Høst-Madsen Medal
Honorary Member		
	Lifetime Achievement	Lifetime Achievement
Distinguished Service Award	Distinguished Practice Award	Distinguished Science Award
	FIP Fellow (FFIP)	FIP Fellow (FFIP)
	Bio-Tech Award	Bio-Tech Award

The following awards were presented in Basel, Switzerland during the FIP Annual Congress:

FIP Lifetime Achievement in the Pharmaceutical Science Award:

Professor H.L. Bhalla (India)

Distinguished Science Award:

Dr Jennifer Dressman (Germany)

FIP Fellows:

Ms Bente Frøkjær (Denmark)

Dr Sabine Kopp (Switzerland)

Prof. Henri R. Manasse, Jr. (USA)

Prof. Peter Noyce (UK)

Mr Prafull D. Sheth (India)

Prof. Yuichi Sugiyama (Japan)



vision

congress report

The FIP Congress

The FIP World Congress of Pharmacy and Pharmaceutical Sciences is the most significant FIP event of the year, integrating fundamental Federation philosophies and each year hosting a growing global audience.

The FIP Congress takes place in a different city around the world on a rotating regional basis, ensuring that the Federation maintains its global presence and accessibility. It is the only truly global event of its kind, inviting pharmacists and pharmaceutical scientists from all manner of practice and discipline to learn, connect with peers and colleagues and be enriched by an international environment.

FIP Congress Basel, 2008

The International Pharmaceutical Federation (FIP) was very pleased to announce a record number of participants in attendance at its 68th World Congress of Pharmacy and Pharmaceutical Sciences held in Basel, Switzerland at the end August and beginning of September. Over 3000 pharmacists, pharmaceutical scientists, academics, researchers, students and press from 120 different countries participated in sessions,

workshops and discussions focused on Re-engineering Pharmacy Practice in a Changing World, the main theme of the 2008 Congress.

FIP was honoured and privileged to welcome Mr Pascal Couchepin, President of the Swiss Confederation, to speak at the Opening Ceremony.

The honoured speaker noted that health is one of society's most important values and that rapid changes in healthcare are affecting us all. Increased health provision has resulted in prolonged life expectancy and remains a driver for economic growth. However, he also brought to the audience's attention future challenges for pharmacists and our partners in healthcare, including the questioning of healthcare systems around the world and increasing costs and structural inefficiencies and inequalities.

The President offered poignant praise for the role of the pharmacist in health care and urged all to take on new and greater tasks and responsibilities, saying that the greater involvement of pharmacists in drug treatment will lead to better therapeutic outcomes and thereby enhances the quality of life of patients in our society.

President Couchepin commended FIP on its job in bringing together so many of the world's pharmacists and pharmaceutical scientists in an event such as the FIP World Congress, and wished all a fruitful conference in the interest of all.

Dr Kamal K Midha also addressed an audience of thousands during the Opening Ceremony, recounting the work and accomplishments of the Federation over the

past year yet stressing that FIP is solidly focused on and preparing for the future with the creation of 2020 Vision: FIP's Vision, Mission and Strategic Plan. Through this plan, which was unanimously supported and ratified by the FIP Council during the Congress, FIP aims to position itself as the global source of information and expertise on medicines use such that whenever and wherever medicines are discussed on a global level, FIP is at the table.

He stressed that the presence of FIP member organisations and more than 3,000 delegates from around the world in Basel underscores who we are – a global network of associations of pharmacists and pharmaceutical scientists committed to effective, safe, affordable, and patient-focused healthcare everywhere.

Dr Midha also went on to relay news of the many inter-professional and multi-disciplinary initiatives being undertaken by the Federation, not the least of which was the First World Health Professions conference on Regulation. This event was co-hosted with FIP's partners in the World Health Professions Alliance and the World Confederation for Physiotherapy. The response exceeded expectations. Over 500 pharmacists, dentists, nurses, physicians, physiotherapists and government officials discussed the critical importance of professional regulation as essential to safe, quality patient healthcare.

Dr Midha held great pride for the accomplishments of FIP and praised all for their hard work and dedication to goals that will ultimately benefit patients around the world.

Throughout the week of pre-satellite symposia, plenary sessions, workshops, meetings, exhibition and poster sessions, FIP Congress Participants were exposed to the most current and relevant issues facing the pharmacy profession and pharmaceutical sciences and invited to play an integral role in their development.

A definite achievement of the 2008 FIP Congress in Basel was the Global Hospital Conference on the Future of Hospital Pharmacy. Hospital pharmacists from around the world met and successfully developed 74 consensus statements reflecting the profession's preferred vision of practice in the hospital setting. The Global Conference on the Future of Hospital Pharmacy was hosted by the FIP Hospital Pharmacy Section.

A total of 348 registrants representing 98 nations met on 30 and 31 August to develop and endorse the list of goals and objectives. Following two days of debate and discussion, all of the consensus statements were approved by the assembled delegates. The statements cover all areas of the medicine use process in hospitals, including the procurement of medicines, preparation and distribution, prescribing, administration of medicines, and the monitoring of patient outcomes. In addition, issues related to human resources and training were addressed. Medication safety was an important consideration in all consensus statement development.

As the biggest global meeting of its kind, the FIP World Congress of Pharmacy and Pharmaceutical Sciences once again offered a unique and invaluable venue for learning and international networking. FIP is looking forward to welcoming participants once again to the 69th Congress in Istanbul, Turkey where the goal is to thoroughly, with vision discuss Responsibility for Patient Outcomes – are you ready?

We are ready.



partnerships

fip-who collaboration report

Introduction by FIP CEO and General Secretary,

Mr A.J.M Hoek

As the global Federation representing the world's pharmacists and pharmaceutical scientists, the concept of Health-for-All is an inherent value within the functioning of the International Pharmaceutical Federation (FIP). Through our ongoing internal projects and initiatives and those in collaboration with our partner organisations such as the World Health Organization (WHO), FIP had been actively advocating for better health through the advancement of pharmacy practice and the pharmaceutical sciences in previous years and particularly spanning 2008-2009.

With a new FIP office established in Geneva, Switzerland in 2008, the Federation aims to continually raise and fulfill expectations amongst pharmacists and engage all partners – including patients – in promoting good health on an engaging, comprehensive and global level.

This report highlights the key milestones and achievements of the collaboration between the Federation and the WHO throughout 2008 and 2009.

The FIP/WHO Year in Review

Strengthening the Pharmaceutical Workforce

The goal of this programme is to document and analyse pharmacy workforce trends and to develop guidance for FIP Member Organisations and other stakeholders on how to address challenges in pharmacy workforce development to support access to and rational use of medicines.

Joint FIP/WHO activities:

- FIP has progressively increased its collaborations with the WHO Human Resources Department. Our contributions in Human Resources for Health include:
 - Formation of a FIP-WHO Pharmacy Education Taskforce. A committee had been established with experts in the field along with representation from WHO. A two year action plan had been developed following the 2006 roundtable consultation which had been formally approved by both FIP and WHO. Funding is being sought to implement the plan;
 - FIP joined the Global Health Workforce Alliance (GHWA). A representative of the FIP-WHO Pharmacy Education Taskforce was invited to join the technical group on scaling up training and education;
 - FIP-WHO Pharmacy Education Taskforce organised the third round table for Pharmacy Education at the 68th FIP Congress in September 2008.

- ↪ FIP led the launch of the Global Tripartite Education Action Plan 2008-2010 with WHO and UNESCO at a joint session held at the Global Health Workforce Alliance Forum for Human Resources for Health in Kampala, Uganda, 6 March 2008.
 - The Action Plan focuses on addressing bottleneck issues in pharmacy education such as academic and institutional capacity, quality assurance, vision and competency. The joint effort of these organisations facilitates a more effective, efficient and concrete approach as well as enabling a multi-sectoral platform for dialogue, learning and sharing of evidence and experience at global, regional and local levels.

- ↪ FIP is working together with WHO and the World Federation of Medication Education to establish a database of health training institutions, including pharmacy schools in 2008. FIP is a formal partner in this initiative and is on the Advisory board. The FIP Academic Section is working together with the WHO Human Resources Department and WFME on this project. FIP has initiated a process of updating its World List of Pharmacy School database since February 2007.

- ↪ FIP, together with support from WHO will be launching a new, online, academic journal on Pharmacy Education in 2009.

Medicines

The overall goal of the programme is to enable better access to and rational use of safe, cost-effective, quality medicines worldwide by improving global cooperation, participation and coordination of medicines related initiatives.

Joint FIP/WHO activities:

- ↪ Since the inception of WHO International Medical Products Anti-Counterfeiting Taskforce (IMPACT)

- in Rome, February 2006, (on behalf of the World Health Professions Alliance, WHPA) FIP has taken a lead role in the Working Group Communications in IMPACT and will be driving forth the risk communications strategy for counterfeit medicines globally. The Federation is currently working on 12 key technical products in the WHO Taskforce
- FIP co-organised the FIP/IMPACT meeting on using technology to combat counterfeit medicines in Singapore, February 2008. This meeting brought together drug regulatory authorities and technology developers from 40 countries. FIP is currently hosting www.impactglobalforum for communications on IMPACT activities. FIP will continue to support WHO in its initiatives to combat counterfeit medical products.
 - During the World Health Assembly 2008, FIP organised a NGO briefing on counterfeit medical products with WHO-IMPACT. This briefing focused on the role of governments, NGOs and international organisations.
 - FIP has an objective to constructively engage the Geneva-based diplomatic Missions and the most relevant NGOs and Civil Society groups in strengthening political commitments so as to raise awareness about the public health risks of counterfeiting, and to bring about unified international actions to combat counterfeit medical products. FIP is leading the development of a World Health Professions Alliance (WHPA) joint position statement on combating counterfeit medical products. FIP will also be working closely with the WHO in engaging open discussions with the diplomatic Missions based on Geneva and the most relevant NGOs in April/May 2009 and onwards.
 - FIP was invited to support the first WHO Congress on Traditional Medicines in November 2008 and to organise a joint symposium on traditional medicines with the World Self Medication Industry. This activity has increased visibility of FIP in the realm of traditional medicines and the role of pharmacists in self-care.
 - WHO revised the WHO Guide on Multisource (Generic) Pharmaceutical Products: Guidelines on registration requirements to establish interchangeability. A FIP/WHO Biopharmaceuticals Classification System (BCS) Taskforce was established and the FIP Board of Pharmaceutical Sciences will continue to be instrumental in the revision process of these guidelines.
 - FIP and WHO published the WHO/FIP Developing Pharmacy Practice: a Focus on Patient Care, Booklet 2006 Edition. This manual served as a tool and a guide for pharmacy training, both in industrialized and resource-constrained countries. A process of field testing was initiated and continued through 2008 and beyond. FIP actively promoted the publication in its Boards. This resource was translated into French, Spanish, and Russian in 2008. Currently, FIP is working with partners on further translation into Chinese, Italian and other languages.
 - FIP organised the first meeting of the FIP Experts Group on Standards for Quality of Pharmacy Services in Basel, Switzerland during its 68th Congress. The meeting had 50 participants in total, including the FIP Working Group on Good Pharmacy Practice (GPP), WHO staff from HQ. The Eastern Mediterranean regional office and WHO country medicines advisors from Ghana, Nigeria and Tanzania, Presidents/ Secretaries of the six FIP regional pharmaceutical forums, invited experts from Management Sciences for Health (MSH), Ecumenical Pharmaceutical Network (EPN) and FIP Member Organisations.
 - FIP attended the WHO Expert Committee on Specifications for Pharmaceutical Preparations meeting in Geneva from 13 to 17 October 2008. The purpose of

this meeting for FIP was to initiate discussions and plans on the revision of the 1993 FIP/WHO guidelines on quality of pharmacy services in the community and hospital settings. It is anticipated that the guidelines will be updated by 2010.

- FIP was invited by WHO to author the Chapter on Human Resources in the pharmaceutical sector in the WHO World Medicines Situation Report 2010. This publication provides a review of the medicine situation in the world.
- A representative from FIP was selected to attend the WHO Technical Briefing Seminar on quality assurance and safety of medicines in September 2008. This meeting was organised to advance collaboration between WHO and stakeholders from governmental and non-governmental organisations such as FIP engaged in promoting the quality and safety of medicines in the global community with the aim of increasing awareness and knowledge of quality assurance and safety of medicines, blood products and related biological with a special focus on WHO standard setting processes.
- FIP was invited to comment on the Third WHO Medicines Strategy within WHO Medium Term Strategic Plan for 2008-2013. Our response was made in the context of the FIP 2020 Vision, The Vision, Mission, and Strategic Plan, approved unanimously by the FIP Council on September 4, 2008 at in 68th Congress in Basel, Switzerland. FIP continues to support the WHO Medicines Strategy, including providing expertise in review of WHO guidelines, participation in Expert Committees or development of any resources relevant to essential medicines and pharmaceutical policy.
- FIP was invited to the first WHO International Classification of Diseases Stakeholders meeting in May 2008. This was a meeting of key stakeholders who

are interested and would like to participate in the revision of the WHO ICD-11. The ICD is the international standard diagnostic classification for all general epidemiological and many health management purposes. These include the analysis of the general health situation of population groups and monitoring of the incidence and prevalence of diseases and other health problems in relation to other variables such as the characteristics and circumstances of the individuals affected.

Patient Safety

The overall goal of the programme is to focus on the contribution of pharmacists in improving patient safety. FIP aims to be a pro-active partner of the WHO Alliance on Patient Safety in its global initiatives, including involvement with the Global Challenges, Small Research Grant Programme, Patient Safety Solutions, Patients for Patient Safety, and African Partnerships for Patient Safety and where medication safety and patient safety are important.

Joint FIP/WHO activities:

- FIP was invited to participate in a communications review meeting of the World Alliance on Patient Safety. Updates were received on the first and second Global Patient Safety Challenge on Clean Care is Safer Care and Safe Surgery. The next patient safety challenge will focus on antimicrobial resistance in 2009-2011. FIP and WHO are currently working intensively to organise a joint symposium on antimicrobial resistance in the 69th FIP Congress in Istanbul, Turkey.
- FIP successfully received funding for its submission of a patient safety project on "Implementation and testing of culture-specific pharmaceutical pictograms for the labelling of medications in Mexico" by the World Alliance on Patient Safety Small Research Grant programme in 2008/2009. This project is an initiative of the FIP Military and Emergency Pharmacy Section.
- FIP initiated discussions with the WHO African Partnerships for Patient Safety on potential opportunities to strengthen our activities and collaborations on the following areas:
 - Input into the WHO hospital situational analysis tool on hospital pharmacy processes. FIP will contribute by designing and defining key questions for the checklist on hospital pharmacy, based on the 6 themes of the Basel Consensus Statements. This will be one of the ways of monitoring the implementation of the Basel Statements and its evaluation in real practice;
 - Develop patient safety tools and advocacy materials on medication use and medication safety issues;
 - Engage national pharmacy associations in African with the activities of the Partnership, especially in regards to the need to establish culturally accepted levels of hospital pharmacy practice standards in the beginning, leading to wider patient safety roles of pharmacists in the health system.

Non-Communicable Diseases

The overall goal of the programme is to support and promote pharmacists' interventions in the prevention and control of non-communicable diseases (inter alia, tobacco cessation and HIV/AIDS). FIP aims to be a pro-active partner in supporting the WHO Global Strategy on Prevention and Control of Non Communicable Diseases and Mental Health, where appropriate, to give input into the implementation of the Global strategy by identifying the specific areas where FIP could contribute or collaborate with WHO.

Joint FIP/WHO activities:

- As a pro-active partner to the WHO Tobacco Free Initiative (TFI) and the Framework Convention on Tobacco Cessation (FCTC), with a specific focus on supporting the implementation of Article 14: Demand reduction measures concerning tobacco

dependence and cessation, FIP continued to be active in promoting the “Global Network of Pharmacists against Tobacco”. The Network was established in order to facilitate collaboration between regional pharmaceutical forums, professional pharmaceutical associations and individual pharmacists in the area of smoking cessation and anti-tobacco activities. The website www.pharmacistsagainsttobacco.org is updated regularly.

- FIP was invited to the WHO/World Economic Forum Global Consultation on Tobacco Treatment in December 2008. A global public/private partnership will be developed as an informal type of consortium of relevant public and private stakeholders.
- As an observer to the WHO FCTC, FIP participated in a meeting of NGOs in January 2009. The consultative meeting covered the areas of cooperation that will advance implementation of the Convention and the decisions of the Conference of the Parties. FIP will continue to working closely with the FCTC secretariat and WHO TFI on establishing mechanisms and resources for strengthening international cooperation and coordination for implementation of the Convention.
- FIP remained in close communication with the WHO HIV/AIDS Department. FIP was invited to the 9th Technical consultation on WHO global recommendations on task shifting, with special regards to the HIV/AIDS situation. Appropriate interventions were delivered by FIP.
- On activities relating to health promotion, FIP was nominated to be a board member of the WHO NGO Alliance on Health Promotion in 2008. The mission of this Alliance is to improve the health and development of all people by generating and sharing knowledge for building a collective NGO voice and to strengthen advocacy, policy and action in the promo-

tion of health. FIP will continue to actively supporting its initiatives including preparations for the lead up activities to the 7th Global Conference on Health Promotion in October 2009.

Other notable collaborations:

- FIP is an official Partner of the WHO Partnership for Maternal, Newborn and Child health (PMNCH) and was represented in the Workshop on Health care professional associations and their role in reaching the Millennium Development Goals 4 and 5 in November 2008 at Dhaka, Bangladesh. FIP continues to advocate the role of the pharmacist in maternal, newborn and child health care.
- FIP released a Press Release on 7th April, World Health Day 2008, emphasising on the value of pharmacists in primary health care. Additional resources were sent to all FIP Member Organisations to support and highlight the added value of pharmacists in the four different areas of reforms in improving primary health care. FIP will continue to support the WHO call for primary health care systems.
- FIP was invited to attend the resumed second session of the Intergovernmental Working Group on public health, innovation and intellectual property at CICG Geneva, 28th April to 3rd May 2008.
- Several representatives from WHO attended the 68th World Congress of Pharmacy and Pharmaceutical Sciences in Basel, Switzerland, as participants and/or speakers.
- FIP delivered expertise and input in the following WHO documents:
 - WHO proposal for revision of Good Distribution Practices for pharmaceutical products (QAS/08.252)
 - WHO Guideline to the inspection of hormone product manufacturing facilities (QAS/08.256)
 - WHO document on the development of paediatric medicines: pharmaceutical development (QAS/08.257)
 - WHO document on procedure for prequalification of medicinal products (QAS/07.248/Rev.1)
 - WHO document on stability testing of active pharmaceutical ingredients and finished pharmaceutical products (QAS/06.179/Rev.3)
 - WHO guideline on transfer of technology (QAS/08.259)
 - WHO recommendations for improvement of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce (QAS/08.279)
 - The following revised proposals for the International Pharmacopoeia
 - Quinine sulphate tablets (QAS /07.219/Rev.1)
 - Chloroquine sulphate oral solution (QAS /07.216/Rev.1)
 - Mebendazole (QAS /08.272/Rev.1)
 - Chewable mebendazole tablets (QAS /07.245/Rev.1)
 - Oseltamivir phosphate (QAS /06.190/Rev.2)
 - Amodiaquine hydrochloride tablets (QAS /07.223/Rev.2)
 - Efavirenz oral solution (QAS /08.280)
 - Nevirapine oral suspension (QAS /07.200/Rev.1)
 - Nevirapine tablets (QAS /07.201/Rev.1)
 - Chloroquine (QAS /08.289)
 - WHO report of the informal expert meeting on dosage forms of medicines for children

FIP would like to take the opportunity to thank Dr Sabine Kopp from WHO for her resolute support to our sustained collaborations.



collaboration

regional pharmaceutical forums

Regional pharmaceutical forums bring together national pharmacy associations, the World Health Organization (WHO) and FIP in six regional platforms. The aim of the Forums is to increase partnership, dialogue, understanding and activity in different world regions, enabling the pharmacy profession to have a greater impact on improving pharmacy services and health by focusing on distinct local needs.

The Regional Pharmaceutical Forums have been formed in WHO's six geographical subdivisions:

- Europe: EuroPharm Forum (est 1992);
<http://www.europharmforum.org>
- America: Pharmaceutical Forum of the Americas (est 2000);
<http://www.paho.org/English/HSP/HSE/ffa-eng.htm>
- South-East Asia: SEARPharm Forum (est 2001);
<http://www.searpharmforum.org/>
- Western Pacific: WPPHarm Forum (est 2001);
<http://www.wppf.org/>
- Eastern-Mediterranean: EmroPharm Forum (est 2002); <http://emropharmweb.com/>
- Africa: APForum (est 2004);

The FIP Latin American Region

During the FIP Congress in Beijing in 2007, the leaders of the regional pharmaceutical organisations in Latin America came together in a very important meeting, called by the FIP President, Dr. Kamal Midha. Although this collaboration had been debated previously, it seemed that the right moment had come to initiate concrete action: there were enthusiastic and proactive leaders in all these regional organisations, a good relationship between them and a willingness to work together.

Therefore, 2008 was definitely the year when such forms of collaboration started taking shape and the fruits of these efforts became (or will soon become) visible.

From September 2008, after the election of Dr. Carmen Peña as Vice-President of FIP, and due to her deep knowledge and dedication to the region, the visibility of FIP in Latin America and its role in the collaborative process were further strengthened. This election of a Spanish-speaking Vice-President was highly valued in Latin America and can have a great impact in further consolidating the relationship between those countries and FIP.

Activities and accomplishments

Declaration of the Americas

The Declaration of the Americas on the Profession of Pharmacy and its Impact on Healthcare Systems was jointly written and signed by FEPAFAR, FEFAS and FFCC, and endorsed by the Pharmaceutical Forum of the Americas, the Spanish Consejo General de Colegios de Farmacéuticos de España and other organisations. This joint statement was the first tangible result of this cooperation and was considered as a very valuable lobbying tool by all national organisations in the region. It has been published in several national publications and websites.

Congress coordination

The various Federations in the Americas took steps towards a more coordinated congress agenda in the region. Namely:

- FEPAFAR will change from a triennial to a biennial congress held alternately in South America and in Central/North America and the Caribbean. The host country will no longer hold the presidency in an automatic manner. Election will be open to any candidates and the Executive Committee will be elected for a two-year term, with the possibility of one re-election.
- FEFAS will organise their congress in 2010 together with FEPAFAR, to test the feasibility of the coordination scheme and the participation of pharmacists from the Central/North American and Caribbean region. It will also start organising smaller meeting on a specific topic.
- FFCC committed to the scheme of a single, annual, Pan-American congress by offering to merge their congress with the FEPAFAR congress in Central America every second year, and to encourage pharmacists in their region to attend the congresses in South America.
- The Forum will have more visibility in these congresses, by organising workshops and seminars.

Relationship with the Pharmaceutical Forum of the Americas

Throughout 2008, contact between FIP and the Forum was mainly focused on ways to consolidate forms of cooperation with the other regional pharmaceutical organisations, to revitalise and broaden the membership base and the participation of member countries and to establish an active permanent secretariat as a key element of this revitalisation of the Forum.

Although this had been discussed in Beijing, it was agreed at the meeting of the Executive Committee of the Forum in Asunción, in March. No decision was made on whether this secretariat would be shared with FEPAFAR until November, when it was finally decided that it would be initially just for the Forum. Costa Rica made a very generous and detailed offer to host the secretariat and this was unanimously approved at the Forum assembly in November. The Forum Secretariat started operating in the first quarter of 2009, with a new professional Secretary.

Other important results achieved in 2008 included the enhancement of the cooperation with FEPAFAR and with the Central American and Caribbean countries through FFCC. Given the history of committed work and forward thinking of the Costa Rican organisation, this secretariat may represent a turning point for the Forum, and results of this change will surely soon be visible.

The WHO/FIP EuroPharm Forum

The EuroPharm Forum (EPF) was founded in January 1992 and is a joint network of national pharmaceutical associations in the WHO European region. The EPF was the first Regional Forum to be established, and is an independent forum. Forum members currently comprise 35 professional associations of pharmacists from 26 countries.

Mission and vision

The mission of the EPF is to improve health in Europe according to priorities set by the WHO. This work is effected through dialogue and collaboration with the national pharmaceutical member associations, with the WHO Europe and other pharmacy-related organisations with observer status, eg FIP and PGEU. The Forum aims to strengthen the position of pharmacists by showing their value to people involved in health issues. The aims of the Forum are:

- To improve health in the WHO European Region;
- To support the implementation of WHO policies in the European region;
- To formulate policy statements on health issues identified at the General Assembly of the Forum;
- To promote the integration of appropriate aspects of WHO policies into basic, postgraduate and continuing pharmaceutical education;
- To strengthen contact between national pharmaceutical associations and between the national pharmaceutical associations and the WHO.

Activities and accomplishments

The main work of the EPF in 2008-2009 has been the following activities: organisation of professional seminars (October 2008); update of the CD-rom toolbox which contains all professional programs made by EPF and a program for sustainable implementation; issue of a report on pharmacists' actions on pandemic influenza; monthly newsletters; change of statutes; signing of

a Memorandum of Understanding for Collaboration between the WHO Regional Office for Europe and the EPF; and setting up of an Observatory.

The Observatory is a web-based initiative that will scan the horizon for pharmacy practise documents. The Observatory aims to ensure members of the EuroPharm Forum easy and reliable access to knowledge, information on developments in pharmacy practice.

The Observatory is a platform where information is gathered and systematised. Materials of the working groups are also displayed. Whenever members have a question concerning pharmacy practice or want to learn about the experiences of other countries, they can access the Observatory to seek information or submit a query.

The Observatory is open to all with an interest in pharmacy practice, at www.europharm.pbwiki.org. The EuroPharm Forum welcomes all who wish to use and contribute to the development of the Observatory.

Due to a change of EPF statutes and a move of the secretariat from the WHO Europe premises to the WHO Collaborating Centre, Pharmakon, the need for a formal collaboration agreement with WHO Europe became evident. The Memorandum of Understanding for Collaboration, specifying the collaboration format, was signed in March 2009. This means, for instance, that EPF president frequently has meetings with Ms Nata Menabde, Deputy Regional Director WHO, Europe; that a representative from the WHO Europe is present at all Executive Committee meetings and professional advice from experts in WHO is available.

The FIP/WHO South-East Asian Pharmaceutical Forum (SEAR)

SEARPharm Forum is a FIP Regional Forum of National Pharmaceutical Organisations in collaboration with WHO Regional Office for South East Asia. Its secretariat is based in New Delhi, India. National pharmaceutical associations of Bhutan, India, Indonesia, Sri Lanka, and Thailand are founding members. Bangladesh, DPR Korea, Maldives, Myanmar, Nepal and Timor Leste are invited.

Mission and vision

The mission of SEARPharm forum is to promote the pharmacist role in WHO's health agenda in the SEA region of WHO. The goals of forum are to improve health in the South-East Asian region by development and enhancement of pharmacy practice (Good Pharmacy Practice); encouraging the implementation of pharmacy service and pharmacy practice projects by national pharmaceutical associations; supporting WHO policies and goals; integrating appropriate WHO policies into undergraduate, postgraduate, and continuing education programmes in pharmacy; formulating policy statements on public health issues and combating the production and distribution of counterfeit medicine and sale of medicine by people who are not qualified.

Activities and accomplishments

In order to promote the development of GPP in the region, the second Regional Conference on GPP Policy and Plans was convened in Yogyakarta from 10-12th August, 2008. The objective of the Conference was to follow up on the outcomes of the first conference held in Bangkok in 2007 and to further develop GPP policies and Plans in SEA Region. Ms. Eeva Terasalmi (Finland) and Dr. Greg Duncan (Australia) were the resource persons from FIP. WHO-SEARO, FIP and Indonesian Pharmacists Association (ISFI) supported the workshop. Thirty-five participants from India, Thailand, Indonesia, Sri Lanka and Myanmar attended the workshop.

In November 2008, the health care professionals associations (HCPAs) affiliated with Partnership For Maternal And Newborn Child Health (PMNCH) met in Dhaka, Bangladesh to discuss issues of Advocacy, Planning, Quality improvement, Human resources, Strengthening of organisational aspects by International/Regional/ National agencies and associations support at country level to reach Millennium Development Goals (MDGs) 4 and 5 in India, Pakistan, Bangladesh, Nepal Myanmar and Afghanistan. The workshop provided pharmacists from the participating countries an opportunity to work together in this important health care initiative of FIP with other HCPs. It is highly necessary for pharmacists from developing countries to integrate themselves with other HCPs towards this goal.

Mr Nasser Zahedee, President of the Bangladesh pharmaceutical society (BPS) organised a seminar on the Development of Hospital Pharmacy for Young Graduates in November 2008. The FIP MOs from Bangladesh, India, Pakistan and Nepal participated. Prafull D. Sheth, Professional Secretary, SEARPharm forum delivered a keynote address. The conference was attended by Dr Anwar Munshi, Joint Secretary, MoH, Bangladesh.

The Indian Pharmaceutical Association (IPA) organised the Indian Congress of Pharmacy & Pharmaceutical Sciences – 2009 & Indian Pharmaceutical Association Convention – in March 2009 at New Delhi. As per Dr B. Suresh, President, IPA, he was inspired by FIP annual congress at Basel. This convention took a thorough look at how the pharmacy profession in India can be re-engineered to meet global challenges. Dr Kamal Midha, President, FIP was the guest of honour. SEARPharm President and ExCo members also participated.

SEARPharm forum held its meeting of the newly constituted ExCo at WHO-SEARO. Mr. Teera Chakajnarodom (Thailand) presided over the meeting and proposed to prioritize GPP in the region as the goal in the activities by formation of the regional team which will be led by the

President. Mr Raj Vaidya (India) and Dr. Dani Pratomo (Indonesia) will be members. The team will focus on the project to accredit pharmacies in the region as SEARPharm forum pharmacies. Various WHO projects reviewed during the ExCo were educational material for Good Pharmacy Practice for use by the National Associations in the Region; collaboration with National Professional Associations of Pharmacists in the region; methods and measures for using existing drug information material for patient information; educational material for Pharmacists in combating counterfeit medicines and database of media reports on counterfeit medicines in the SEARPharm Forum website.

On a request for a Resource Person from Ms. Margaret Evan, Coordinator, Global Projects Pricing, Health Action International (HAI) to Dr K. Weerasuriya, Mr Prafull D. Sheth met with her at the Hague on 1st Feb 2009. Mr Sheth shared with Ms Evan the report of SEARPharm forum on medicine prices in SEA region and methodology for drug pricing processes involved in determining conversion costs of finished dosage forms which was highly appreciated.

The WHO/FIP Western Pacific Pharmaceutical Forum

President, John Ware, OAM President, Australia

Vice-President, Wai Keung Chui, Singapore

The Western Pacific Pharmaceutical Forum was established in 2001 and has entered the period of consolidation in its role of interaction with the World Health Organization regional office in Manila and in its role as a networking agent with the FIP Member

Organisations in the Western Pacific region.

Two major roles for the Forum are starting to emerge. Firstly, as a coordinator of programmes to help developing and transitional countries in our region to achieve modern standards of pharmacy practice and education. The work currently being undertaken in Vietnam and our completed work on a review of pharmacy education in the Western Pacific region and ongoing programs relating to competence and education that are currently looking to the future, are very good examples of this.

The second and equally major role is to act as a networking and information agent by bringing together our region's pharmacy associations with a continuous flow of reports from all countries, being circulated through the Western Pacific region. This is now being developed further through our website by establishing networking links for both hospital and academic pharmacists.

Mission and vision

The importance of the Forums to FIP and the pharmacy profession generally in each of the six world health regions is shown in FIP's newly adopted mission vision and strategic plan titled '2020 Vision'.

Within the vision statement, FIP's three strategic objectives fit perfectly with the plan and objectives of the Western Pacific Pharmaceutical Forum. Particularly, the Western Pacific Pharmaceutical Forum and its regional

counterparts have a big role to play in FIP's tactical approaches of:

- Building constructive partnerships
- Increasing the visibility of FIP in the global environment
- Increasing effective communications

The Forum is clearly recognised in the guidelines which state that 'FIP will evaluate the concept and activities of the Forums in enhancing the impact of FIP at the regional offices of WHO and FIP's member organisations within the region' as well as 'development of communications networks amongst many FIP's internal structures such as the Boards and Forums etc'.

This new vision of FIP will give not only the Western Pacific Pharmaceutical Forum, but all the Forums, an opportunity to look to the future with great confidence in our role of bringing the global pharmacy message to the associations and the World Health Organization in our region.

All our regional organisations are encouraged to obtain and read carefully FIP's '2020 Vision'. It was developed exclusively for our associations as members of FIP as global vision for pharmacy. The strength of the global federation of pharmacy associations, FIP, can do much to increase the status of the pharmacist and empower members to influence global and regional health issues.

To this end, the Forum has had translated the 2020 Vision statement into Mandarin, Japanese and Korean and has had them published on our website.

Activities and accomplishments

Pharmacy Practice

Changes to the practice of pharmacy continue at great pace throughout the region, particularly in areas relating to prescribing and dispensing.

The Forum is now embarking on plans in an endeavour to bring both hospital pharmacists and academic pharmacists within the region into a much closer interactive networking involvement.

After each meeting of the Forum Executive, minutes of the proceedings are sent to the Presidents and CEOs of all the pharmaceutical associations in the Western Pacific region. As these minutes also contain the reports from each country, we hope and trust that these reports are circulated as widely as possible to Councils and members so that we are all kept up to date with regional developments in practice.

The Forum has continued to strengthen its links with Mongolia, Cambodia and with Papua New Guinea. Papua New Guinea has, for the first time, established a national pharmaceutical society.

One of the Forum's greatest concerns is that in the area better known as 'Oceania', all the small island countries in the Pacific region, there are only two formal pharmaceutical societies, one in Fiji and the other as just mentioned, in Papua New Guinea. There are links to the French association in both Polynesia and New Caledonia. We look forward to developments in the next year.

Community Practice

Japan, China Taiwan, Korea and the Philippines have all undergone many changes in relation to prescribing and dispensing of medicines. Cognitive services such as medicine reviews and other similar programs are making great strides in Japan, Australia and New Zealand. China Taiwan is reviewing ways and means of introducing these cognitive services such as medicine reviews into their country. The China Taiwan Department of Health sent a team of pharmacists to Australia to investigate home medicines reviews and a selected speaker was subsequently invited to address pharmacists in China Taiwan.

Through its master plan, as will be mentioned later in this report, Vietnam continues to move forward with its strategy to completely change the method of distribution of medicines in that country by 2010.

Hospital Practice

The Forum spent much time promoting the special seminar recently held at the FIP Congress, Basel, on the future of hospital pharmacy practice and we are happy to report that many pharmacists from within the Western Pacific Region took the opportunity to attend this special seminar.

Following the publication of the statements from the global conference and after consultation with the Executive of the hospital pharmacy section of FIP the Forum has agreed to embark on a program supporting promotion and promulgation of the statements.

The statements have already been translated into Mandarin and are in the process of translation into Japanese and Korean. A translation into Vietnamese will commence shortly.

The Forum will process a series of questionnaires relating to the statements in the appropriate language of countries of the region.

Pharmacy Education in the Western Pacific Region

The Forum has followed up the successful publication of a CD of a review of pharmacy schools and pharmacy undergraduate education, registration and licensing requirements in the Western Pacific region, with a further questionnaire to determine whether or not undergraduate curriculum is determined by standards of competence.

Following on from this and also in line with the FIP's global education taskforce, the Forum is developing a submission to the World Health Organization WPRO

with the objective of arranging a workshop of academic pharmacists from the region to discuss the development of curriculum and competency standards. The final proposal was agreed to at the Forum's Executive meeting in March 2009 and has been forwarded to WHO regional office in Manila.

Restructuring Pharmacy Practice in Vietnam

Probably the largest project yet undertaken by the Forum. Following a request from the state drug administration of Vietnam and the pharmaceutical association in Vietnam, the Forum has undertaken the following projects in relation to Good Pharmacy Practice in Vietnam.

- At the request of the government of Vietnam developed draft GPP statutes for the Drug Administration of Vietnam. These statutes were adopted by the Department of Health of Vietnam and passed into statute law in 2007.
- The Forum developed checklists for the GPP statutes in Vietnam for use by pharmacists and government inspectors.
- WPPF, with financial support from the World Health Organisations and lecturers from the National University of Singapore and Monash University Australia, conducted 'train the trainer' programs in Hanoi and Ho Chi Minh City, training 140 pharmacists in Vietnam to train others in the GPP statutes and requirements
- DAV and Vietnam Pharmaceutical Association have, to date, trained over 3,000 pharmacists in the new requirements and has accredited over 600 pharmacies for the new standards. 86 of 110 hospital pharmacies have also been accredited to the new standards.

For the major cities of Hanoi and Ho Chi Minh City, the government has determined to reach the standards by 2010. Pharmacies not reaching the required standard will be required to close. Smaller cities and rural areas are expected to reach GPP statute standards by 2015.

Interaction with the World Health Organization

Dr Budiono Santoso, Pharmaceutical Advisor, Western Pacific Regional Office of WHO, is a regular attendee of meetings of the Forum and is frequently accompanied by other members of staff who have areas of special interest. This is helping to create a greater understanding in his department about the work of the Forum. This interaction also enables the Forum to understand the scope of work and influence of WHO in our region.

WHO has recently funded two specific projects on behalf of the Forum, one a seminar on communication techniques for pharmacists held in Manila, the Philippines that attracted pharmacists from some four countries and more recently, the 'train the trainer' programs conducted in Vietnam in relation to the new statutes for good pharmacy practice in Vietnam.

Currently, a submission for a workforce on curriculum development has been lodged.

The Western Pacific Pharmaceutical Forum/ FIP Foundation Scholarships

The FIP Foundation supports the Forum to fund two scholarships each year to the FIP Congress. Scholarships to the FIP Congress in Basel, Switzerland were awarded to Ms Anh Dao Nguyen from Vietnam, who was involved in the training programs for pharmacists in Vietnam on GPP and to Mr Eric Salenga a young pharmacist from the Philippines. Independent funding was provided by pharmacy organisations within the region to send another four young pharmacists to the FIP Congress in Basel. The Taiwan Society of Health-System Pharmacists provided funds to send Ms Katrina Chou and Ms Wen-Chih Chen, The Australian College of Pharmacy Practice and Management provided a scholarship to Ms Georgina Lippis from Australia to attend the congress and the Pharmaceutical Defence Limited, the Australian pharmacists indemnity company and the Pharmacy Guild of Australia provided a scholarship to Mr Edward Nanatsi from Papua New Guinea to attend the

Congress and also to investigate and experience hospital pharmacies in Great Britain.

The Forum hopes that the example set by China Taiwan and the Australian organisations will be followed in future to give young pharmacists an opportunity to meet with their colleagues internationally. Many of the scholarships awarded over the last few years have been awarded to young pharmacists from a wide group of countries from around the region, most of whom are already emerging as leaders in the pharmacy communities in their countries.



members

member organisations

The FIP Member Organisations are the cornerstone and governing body of the Federation. They comprise the FIP Council, which meets on a yearly basis at the FIP Annual Congress to vote on issues pertaining to the future work and direction of FIP, as to contribute and vote on Policy Statements and Guidelines aimed at advancing and advocating the roles of pharmacists and pharmaceutical scientists in delivering better healthcare worldwide.

The FIP Members are our connection to individual pharmacists, pharmaceutical scientists and in turn patients. We thank them for their constant contribution to the work of FIP and their dedication to advancing our mutual mission and vision.

FIP Member Organisations

- Pharmacists Order of Albania
- Confederación Farmacéutica Argentina
- Pharmprogress NGO
- Australasian Pharmaceutical Science Association
- Pharmaceutical Society of Australia
- Pharmacy Guild of Australia
- Österreichische Apothekerkammer
- Österreichischer Apothekerverband
- Bangladesh Pharmaceutical Society
- Association of Pharmacists of the Federation of Bosnia and Herzegovina
- Pharmaceutical Society of the Republika Srpska
- Federal Council of Pharmacy
- Ordre National des Pharmaciens du Burkina Faso
- Conseil National de l'Ordre des Pharmaciens du Cameroun
- Canadian Pharmacists Association
- Canadian Society for Pharmaceutical Sciences
- Chinese Pharmaceutical Association
- Pharmaceutical Society of China Taiwan
- Taiwan Society of Health-System Pharmacists
- Colegio Nacional de Químicos Farmacéuticos de Colombia
- Conseil National de l'Ordre des Pharmaciens du Congo
- Colegio de Farmacéuticos de Costa Rica
- Conseil National de l'Ordre des Pharmaciens de Côte d'Ivoire

- Croatian Pharmaceutical Society
- Sociedad Cubana de Ciencias Farmaceuticas
- Cyprus Turkish Pharmacist Association
- Czech Pharmaceutical Society
- Danmarks Apotekerforening
- Pharmadanmark
- Pharmaceutical Society of Egypt
- Syndicate of Pharmacists in the Arab Republic of Egypt
- Eritrean Pharmaceutical Association
- Ethiopian Pharmaceutical Association
- Association of Finnish Pharmacies
- Finnish Pharmacists Association
- Finnish Pharmacists Society
- Pharmaceutical Chamber of Macedonia
- Association de Pharmacie Galénique Industrielle
- Conseil National de l'Ordre des Pharmaciens
- Fédération des Syndicats Pharmaceutiques de France
- Société Française de Pharmacie Clinique
- Syndicat National des Pharmaciens des Établissements Publics de Santé
- Syndicat National des Pharmaciens Praticiens Hospitaliers et Praticiens Hospitaliers Universitaires
- Union des Syndicats de Pharmaciens d'Officine
- Bundesvereinigung Deutscher Apothekerverbände
- Pharmaceutical Society of Ghana
- Conseil National de l'Ordre des Pharmaciens de Guinée
- Pharmaceutical Society of Hong Kong
- Hungarian Association of Private Pharmacists
- Hungarian Society for Pharmaceutical Sciences
- Pharmaceutical Society of Iceland
- Indian Pharmaceutical Association
- Indonesian Pharmacists' Association
- Iraqi Pharmaceutical Association
- Pharmaceutical Society of Ireland
- Pharmaceutical Association of Israel
- Federazione Ordini Farmacisti Italiani
- Federfarma
- Academy of Pharmaceutical Science & Technology
- Japan Pharmaceutical Association
- Pharmaceutical Society of Japan
- Jordan Pharmaceutical Association

- Pharmaceutical Society of Kenya
- Korean Pharmaceutical Association
- Pharmaceutical Society of Korea
- Kosova Pharmaceutical Society
- Kuwait Pharmaceutical Association
- Pharmacists' Society of Latvia
- Ordre des Pharmaciens du Liban
- Lithuanian Pharmaceutical Association
- Association des Pharmaciens Hospitaliers
du Luxembourg a.s.b.l.
- Syndicat des Pharmaciens Luxembourgeois asbl
- Ordre National des Pharmaciens de Madagascar
- Malaysian Pharmaceutical Society
- Conseil National de l'Ordre des Pharmaciens du Mali
- Association of Pharmacists of Republic of Moldova
- Mongolian Pharmaceutical Association
- Conseil des Pharmaciens Biologistes
- Conseil Régional des Pharmaciens d'Officine du Nord
- Graduate Pharmacists' Association of Nepal
- Koninklijke Nederlandse Maatschappij ter bevordering
der Pharmacie
- Nigerian Association of Industrial Pharmacists
- Pharmaceutical Society of Nigeria
- Norges Apotekerforening
- Norges Farmaceutiske Forening
- Norsk Farmasøytisk Selskap
- Colegio Nacional de Farmacéuticos de Panamá
- Asociación de Químicos Farmacéuticos del Paraguay
- Philippine Pharmacists Association
- Polish Pharmaceutical Society
- Associação Nacional das Farmácias
- Ordem dos Farmacêuticos
- Association Rwandaise de Pharmaciens
- Ordre National des Pharmaciens du Sénégal
- Pharmaceutical Chamber of Serbia
- Pharmaceutical Society of Serbia
- Pharmaceutical Society of Singapore
- Slovensko Farmacevtsko Društvo
- Consejo General de Colegios Oficiales de Farmacéuticos
- Sociedad Española de Farmacia Industrial y Galénica
- Pharmaceutical Society of Sri Lanka
- Sudanese Pharmacists Union
- Apoteket AB
- European Federation for Pharmaceutical Sciences
- Sveriges Farmaceutförbund
- PharmaSuisse
- Pharmaceutical Association of Thailand
- Ordre National des Pharmaciens de Tunisie
- Turkish Pharmaceutical Technology Scientists' Association
- Turkish Pharmacists Association (Türk Eczacıları Birli i)
- Pharmaceutical Society of Uganda
- Academy of Pharmaceutical Sciences
- Royal Pharmaceutical Society of Great Britain
- American Association of Pharmaceutical Scientists
- American Pharmacists Association
- American Society of Health-System Pharmacists
- Asociación de Química y Farmacia del Uruguay
- Vietnamese Pharmaceutical Association
- Pharmaceutical Society of Zambia
- Pharmaceutical Society of Zimbabwe



science

board of pharmaceutical sciences

A report from the Scientific Secretary

Dr. Vinod P. Shah, USA

The FIP Board of Pharmaceutical Sciences is pleased to report a highly successful year of activities and involvement on behalf of the Executive Committee, Special Interest Groups, and Members alike.

Board of Pharmaceutical Sciences

The BPS held two official meetings, the first during the FIP Congress in Basel, Switzerland on 31 August 2008 and the second in The Hague, The Netherlands on 7 March 2009 and an informal meeting at the time of AAPS Annual meeting in November 2008. Throughout the year the Board furthered its goal of establishing itself as the leading global forum for pharmaceutical scientists by organising quality scientific programs and following through with several very successful outreach programs (Regulatory Science; Hands on Dissolution and Bioequivalence; Biotechnology and Quality workshops) in developing countries.

Pharmaceutical Sciences World Congress (PSWC) 2010

BPS holds a scientific congress every 3 to 4 years in different regions of the world. The congress addresses cutting edge science and technology. The next Pharmaceutical Sciences World Congress will be held in co-operation with AAPS in New Orleans, USA, November 14-18, 2010. FIP/BPS members are actively involved with the organisation of PSWC 2010.

Pharmaceutical Sciences 2020

BPS decided to look into the future of Pharmaceutical Sciences, what it will be and what are the possible changes that may occur in 2020. For this, BPS held a preliminary meeting in December 2007 to discuss Pharmaceutical Sciences 2020. A follow up meeting was held in October 2008 in Amsterdam, The Netherlands. About 30 global leaders, pharmaceutical scientists, bankers, venture capitalists, Pharma leaders, regulators and other Stakeholders who have direct or indirect influence in pharmaceutical sciences participated in the meeting. A report of the deliberations will have been published in the 2009 Volume 1 Edition of the FIP International Pharmacy Journal (IPJ).

Special Interest Groups

The BPS has 10 Special Interest Groups (SIGs), each group has co-chairs representing different parts of the globe. The BPS has initiated a separate annual meeting in spring with all SIG co-chairs to invigorate the SIG activities, discuss

science and harmonize all BPS science activities. SIGs also provide input into the upcoming Science program for the Annual Congress.

The BPS has historically been highly involved in the Bio-International conferences, which are held every two years and aim to discuss and resolve complex issues in bio-availability and bioequivalence (BA/BE). These discussions are held on a FIP-BPS neutral platform with academia, industry, and regulators and aim to reach international understanding and harmonization within these specialised fields. The last Bio-International conference, focused on "Towards Improved Harmonization in Regulating Multisource Products" was organized in London, October 22-24, 2008. A pre-satellite workshop on "What is new in In vitro Release?" was also held in London. Both the events were successful with good audience participation.

BPP-IPS and BPS has jointly initiated Quality-International Workshops, held every two years, alternatively with Bio-International Workshops in London. This year, the event will be held on October 12-13, 2009 in London with a theme of "Managing quality across supply drug supply chain: From product inception to patient utilization".

One of the major activities of BPS is the outreach educational and regulatory science program. Themes of these activities are to facilitate expertise and knowledge transfer on specific issues, mainly in developing countries. This includes 'hands-on-dissolution' workshop, regulatory bioavailability/bioequivalence workshop, biotechnology workshop and quality workshop. This year the "Hands-on-Dissolution" workshop was held in Montevideo, Uruguay in November 2008 and "To and Thru the Skin" workshop in Mumbai, India in February 2009.

Events in Brief:

- BPS has now added 'BPS official meeting in spring' to further enhance communication, discussion and dissemination of Scientific activities;
- BPS Exco is now reviewing its Strategic Plan to align it with FIP 2020 Vision and Pharmaceutical Sciences 2020 report;
- In order to increase the interactions between and within the BPS Special Interest Groups (SIGs) and to enhance their input into BPS activities, the BPS continued their spring annual 'all SIGs co-chairs meeting';
- A vaccine workshop was held in September 15-17, 2008. This was organized by EUFEPS and BPS in cooperation with AAPS;
- A pre-satellite workshop on "Special dosage form – in vitro release was held on October 20-21, 2008 in London;
- Bio-International Conference on "Towards improved harmonization in regulating multisource products" was held in London, October 22-24, 2008;
- SIG Natural Products collaborated with WHO in developing a TCM workshop program in China, November 7-9, 2008 at the WHO Congress on Traditional Medicines;
- The SIG Individualized Medicine organized a workshop with AAPS in US in November 2008. This was the third workshop in the series going around the globe;
- Hands-on-Dissolution workshops was held in Uruguay in November 2008;
- "To and Thru the Skin" (Topical and transdermal) workshop was organized in Mumbai, India in February 2009.

Predominent Scientific Member Organisations (PSMOs)

Two new PSMOs have joined FIP/BPS this year. (1) Pharmaceutical Society of China Taiwan and (2) European Federation for Pharmaceutical Sciences (EUFEPS).

BPS tries to interact with its PSMOs to develop workshops, symposia and other scientific activities. The BPS Chair and/or the Scientific Secretary met with AAPS, CRS, EUFEPS, PSJ, APSTJ, TUFTAD and PSK leadership separately at their annual meeting to discuss better interactions with FIP and collaboration in scientific programs.

BPS Public Policy

BPS, through its chair is working on developing three important policies (1) Medicines for children (2) Therapeutic Equivalence and (3) Biosimilars. The policy on Medicines for Children was presented, discussed and approved at the Council meeting in Basel, Switzerland at the FIP Congress in September 2008.

FIP/BPS Awards

The BPS recognises its scientists by bestowing FIP Awards. In 2008, FIP bestowed FIP Lifetime Achievement Award to Professor H. L. Bhalla of India and FIP Distinguished Scientist Award to Professor Jennifer Dressman of Germany.

BPS/BPP Interactions

Members of the two boards are working together to bridge the gap between science and practice. Examples of this include (1) interactions with FIP/IPS in holding joint workshops as well as symposia at annual congress (2) translational science, how science can/will influence practice.

Financial Status

BPS is in a financially sound situation, and has a reserve over Euros 100,000 to its credit from the profits of international workshops.

Conclusions

The BPS is pleased with the accomplishments of 2008-2009, and looks forward to continued active involvement in the coming years whereby the current Strategic Plan will be used a guiding document.

The FIP Board of Pharmaceutical Sciences and Special Interest Groups

The pharmaceutical sciences have been at the foundation of the International Pharmaceutical Federation (FIP) since its conception almost 100 years ago, and throughout this time various specialised fields of pharmacy and science have played an integral role in the success and evolution of the Federation. Now tended by the Board of Pharmaceutical Sciences, this branch of the Federation encompasses ten Special Interest Groups guided by the following mission:

Mission and vision

The mission of the BPS is to establish and maintain itself as the leading forum for the advancement of pharmaceutical sciences and technology worldwide by building strong alliances which foster the sharing of knowledge and facilitate global discovery, development, manufacture, and utilization of high quality, safe and effective medicines.

The BPS Special Interest Groups serve the distinct needs of those involved in very specific and dedicated branches of the pharmaceutical sciences. Through their work and initiatives, global networks of specialists have been established, fostering communication and the sharing of knowledge within and between pharmaceutical scientists the world over.

The BPS Special Interest Groups (SIGs)

SIG Bioavailability/Bioequivalence (BA/BE)

In 1994, BPS established a Special Interest Group (SIG) in the area of bioavailability/bioequivalence (BA/BE) to address controversial and complex issues in the area of BE. One of the important activities of SIG BA/BE has been holding Bio-International Conferences. These conferences are held to discuss and resolve complex issues in BA/BE and to reach international understanding and harmonization. Since last few years, these Bio-International Conferences are held in London in co-sponsorship with Royal Pharmaceutical Society of Great Britain, the last in October 2008.

Initially, this SIG had two working groups (WG), Dissolution WG and Biopharmaceutics Classification System WG. These two WGs have now been developed into SIGs to more attentively serve the needs of pharmaceutical sciences working in these highly focused areas.

Co-Chair: Dr. Vinod P. Shah, USA

SIG Biopharmaceutics Classification System

This SIG Aims to provide an independent platform for scientific discussions between academia, industry and regulators on the possibilities and the limitations of biowaivers for in vivo bioequivalence studies based on Biopharmaceutics Classification System (BCS). The group publishes biowaiver monographs for Active Pharmaceutical Ingredient (APIs) of the World Health Organisation (WHO) List of Essential Medicines. From March 2008 to March 2009, seven new monographs were published in the J Pharm Sci, the official journal of the FIP BPS. They are available on the FIP website.

Co-chairs: *Dr Dirk Maarten Barends, The Netherlands*
Dr James Polli, USA

SIG Dissolution/Drug Release

The major activity of the group has been to plan and organise workshops in the area of dissolution/drug release, develop dissolution guidelines, resolve complex issues related to dissolution and attempt to standardize global "dissolution tests". Previous to their establishment as a SIG the former working group developed (1) "FIP Guidelines for Dissolution Testing of Solid Oral Products" and (2) "FIP/AAPS guidelines for dissolution/in vitro release testing of novel/special dosage forms. Workshops were also established with the WHO to provide proper training for and understanding of dissolution tests to scientists in developing countries. One of the major outreach activities of this group is the Hands-on-Dissolution workshop, to train and educate people on how to perform the important test of dissolution. These workshops have been held globally in various countries.

Co-chairs: Mrs Cynthia K. Brown, USA

Dr Horst-Dieter Friedel, Germany

SIG Individualized Medicine

Individualized medicine is an area which has of late attracted much attention and many influential researchers. As this up-and-coming area makes full use of the latest in medical and scientific developments, individualized medicine will be an important domain in the medical spotlight in many years to come. Its potential to influence current and new treatments and treatment protocols will expand throughout drug design and pharmaceutical care, making individualized medicines a major contributor to the pharmaceutical science and practice process from start to finish, and as such is key area of focus for FIP. The SIG held very successful workshops in Tokyo, Japan in February 2006 and in The Netherlands in November 2007.

Co-chairs: Prof. Hitoshi Sasaki, Japan

Mrs Anke-Hilse Maitland-van der Zee,

The Netherlands

Dr. Majid Moridani, USA

SIG Natural Products

In 2003 a Special Interest Group on Natural Products was established within the FIP Board of Pharmaceutical Sciences. Although medicinal plants are of continuing interest as a source of lead molecules and also as phytopharmaceuticals (especially those commonly called 'herbal remedies'), it is recognized that there is much research interest in substances and compounds from other parts of the biosphere.

The aims of the group are to promote the pharmaceutical sciences relevant to the study of natural products, educate pharmacists in research developments related to drug discovery from natural sources and in the pharmacology and interactions of natural extracts used in pharmacies, and to disseminate novel findings related to the potential and realised use of compounds and extracts in pharmacy, especially from a cross-cultural point of view.

Co-chairs: Prof. Toshio Honda, Japan

Dr Carmen Tamayo, USA

SIG Pharmaceutical Biotechnology

The SIG Pharmaceutical Biotechnology was formed in 1994 to provide a worldwide, neutral and independent platform for discussions on biotechnological issues related to the pharmaceutical sciences. The two areas of primary focus are worldwide harmonisation of regulations for biotech products, seen as a major goal of the SIG, and bridging the educational gap between biotechnologists and "classical" pharmaceutical scientists, formerly two separate and unconnected groups under the Pharmaceutical Biotechnology umbrella.

The major aim is to advance an understanding of and stimulate progress in Pharmaceutical Biotechnology through workshops, conferences and meetings both within and outside of the FIP activities.

Co-chairs: Prof. Gavin Brooks, UK

Prof. Hideyoshi Harashima, Japan

Dr Siddhart Advant, USA

SIG Pharmacoepidemiology and**Pharmacoeconomics**

The SIG Pharmacoepidemiology and Pharmacoeconomics is primarily concerned with what the role and effect of medicines after their delivery for patient use, subsequent to extensive pre-marketing pharmaceutical and clinical research. Keeping track with the course of events (both clinical and economic) connected to a new drug after marketing authorization is granted is a field of growing interest among pharmaceutical scientists, practitioners and policy makers. Ensuring patient safety, risk management and cost-effectiveness in the drug use system are at the top of the public health priority chart, and pharmacists and pharmaceutical scientists are essential players in the development and outcome of these issues.

Through various FIP events and activities this SIG is in place to, amongst other things, stimulate research in pharmacoepidemiology and –economics; to foster communication between scientists, practitioners, regulators and policy makers; to develop and promote scientific standards for epidemiology and economic product evaluations; and to follow the outcome of medicines use on a population level.

Co-chairs: Prof. Bert Leufkens, The Netherlands
Prof. Brenda J. Waning, USA

SIG Radiologic and Nuclear Pharmacy

The SIG Radiologic/Nuclear Pharmacy was founded in 1997 to provide an international venue for Radiologic and Nuclear Pharmacy scientists and practitioners. The SIG supports the advancement of healthcare through the promotion of emerging scientific findings in the practice of pharmacy, support of the development of pharmacy services and by providing a forum of expert opinion to promote harmonization of inter-professional disciplines worldwide.

Specific goals of the SIG include the harmonization of educational methodologies and practice guidelines and

requirements to meet competency levels for pharmacists in radiologic/nuclear pharmacy and to facilitate the development of radiologic/nuclear pharmacy services in countries that are underserved by pharmacists.

Co-chairs: Dr Clyde N. Cole, USA
Dr Eduardo Savio, Uruguay

SIG Medicinal Chemistry

Medicinal Chemistry is one of the important disciplines in drug discovery and development. BPS has established this new SIG this year to fill the need of pharmaceutical scientists in the field of Medicinal Chemistry. The SIG began its work in 2008 with the aim of organising its first sessions at the FIP Congress 2010 in Lisbon.

Co-chairs: Dr. Shigeki Sasaki, Japan
Dr. Ulrike Holzgrabe, Germany

SIG Environment and Pharmaceuticals

Many kinds of chemicals including pharmaceuticals having carcinogenic and endocrine disrupting activity are released in the environment. These pollutants threaten healthy human life. This type of environmental concern is very important for both researchers and pharmacists. The new SIG "Environmental and Pharmaceuticals" established during the FIP Congress 2008 will discuss their analysis and countermeasure and will propose an action plan to reduce the diseases caused by environmental pollution.

Co-chairs: Dr. Kazuichi Hayakawa, Japan
Dr. Bent Halling-Sørensen, Denmark

The Special Interest Groups of the FIP Board of Pharmaceutical Sciences are at the cutting edge of all that is shaping the world of pharmaceutical sciences and research, and in turn medicines, their effectiveness and the overall health of patients.

Members of the FIP Board of Pharmaceutical Sciences

- **Prof. Mitsuru Hashida**
Chairman of the Board of Pharmaceutical Sciences
- **Dr Vinod P. Shah**
FIP Scientific Secretary/Chair SIG BA/BE
- **Prof. Daan J.A. Crommelin**
Imm. Past Chairman BPS
- **Prof. Kamal K. Midha**
FIP President
- **Mr Ton J.M. Hoek**
FIP General Secretary
- **Prof. Henri R. Manasse, Jr.**
FIP Professional Secretary
- **Dr Mario Rocci, Jr.**
Member of BPS ExCo/FIP Vice President/Chair PSWC 2010
- **Prof. Geoffrey T. Tucker**
Member of BPS ExCo/FIP Vice President/PSWC 2010
- **Dr Dirk Maarten Barends**
Co-Chair SIG Biopharmaceutics Classification System
- **Prof. James Polli**
Co-Chair SIG Biopharmaceutics Classification System
- **Mrs Cynthia K. Brown**
Co-Chair SIG Dissolution/Drug Release
- **Dr Horst-Dieter Friedel**
Co-Chair SIG Dissolution/Drug Release
- **Prof. Bent Halling-Sørensen**
Co-chair SIG Environment and Pharmaceuticals
- **Prof. Kazuichi Hayakawa**
Co-chair SIG Environment and Pharmaceuticals
- **Dr Anke-Hilse Maitland-van der Zee**
Co-Chair SIG Individualized Medicine
- **Dr Majid Moridani**
Co-Chair SIG Individualized Medicine
- **Prof. Hitoshi Sasaki**
Co-Chair SIG Individualized Medicine
- **Prof. Ulrike Holzgrabe**
Co-Chair SIG Medicinal Chemistry
- **Prof. Shigeki Sasaki**
Co-Chair SIG Medicinal Chemistry/Delegate of PSJ

- Prof. Toshio Honda
Co-Chair SIG Natural Products
- Dr Carmen Tamayo
Co-Chair SIG Natural Products
- Mr Clyde N. Cole
Co-Chair SIG Nuclear Pharmacy
- Dr Eduardo Savio
Co-Chair SIG Nuclear Pharmacy
- Dr Siddharth J Advant
Co-Chair SIG Pharmaceutical Biotechnology
- Prof. Gavin Brooks
Co-Chair SIG Pharmaceutical Biotechnology
- Prof. Hideyoshi Harashima
Co-Chair SIG Ph. Biotechnology/Delegate of APSTJ
- Prof. Bert Leufkens
Co-Chair SIG Pharmacoepidemiology/economics
- Prof. Brenda J. Waning
Co-Chair SIG Pharmacoepidemiology/economics
- Prof. Patrick P. DeLuca
Delegate of AAPS
- Dr Karen Habucky
Delegate of AAPS
- Mr John Lisack, Jr.
Delegate of AAPS
- Prof. Elias Fattal
Delegate of APGI
- Prof. Ross A. McKinnon
Delegate of APSA
- Prof. Bill Dawson
Delegate of APSGB
- Prof. Tsuneji Nagai
Delegate of APSTJ
- Prof. Gordon McKay
Delegate of CSPS/Expert Member (2008)
- Mr Hans H Lindén
Delegate of EUFEPS
- Prof. T. Ishikawa
Delegate of PSJ
- Prof. Jun Haginaka
Delegate of PSJ
- Dr In Koo Chun
Delegate of Pharmaceutical Society of Korea
- Prof. Juan M. Irache
Delegate of SEFIG/President of SEFIG
- Prof. Atilla A Hincal
President of TUFTAD
- Mr Ragnar Salmen
Delegate of NPS/Observer
- Prof. Yilmaz Çapan
Expert Member (2008)
- Prof. Jennifer Dressman
Expert Member (2008)
- Prof. Jin-Ding Huang
Expert Member (2004)
- Dr Sabine Kopp
Expert Member (2006)
- Dr Robert Powell
Expert Member (2008)
- Dr Chang-Koo Shim
Expert Member (2008)
- Mr Ajit Singh
Expert Member (2004)
- Prof. Salomon Stavchansky
Expert Member (2004)
- Prof. Shinji Yamashita
Expert Member (2008)
- Dr Robert Bell
Expert Member PSWC 2010
- Dr Ho-Leung Fung
Expert Member PSWC 2010
- Ms Sónia Faria
YPG Chair/Observer
- Mr John Nguyen
IPSF President/Observer



practice

board of pharmaceutical practice

A report from the Professional Secretary

Dr Henri Manasse Jr, USA

Today's global healthcare environment is increasing complex, costly and in constant review by public policy analysts, politicians, public critics and a host of other observers. Whether a developed country, a nation in economic transition, or a developing country, none are immune from both scrutiny of and planning for the health care sector. Most of the focus is on financing, quality and safety but there is also deliberation around issues of workforce development, access to care and globalization of disease and its prevention and management.

The profession of pharmacy has not been immune from the issues and pressures debated in the public space. Every segment of the profession is engaged in review and planning for maintaining the scope and quality of their practice while simultaneously contemplating their future. The Board of Pharmaceutical Practice, with its nine Sections has spent considerable time, energy and effort to guide the Sections and to listen to the Sections as it implements its Strategic Plan.

Section Activity

Each of the Board's nine Sections has ongoing effort in the planning and execution of the FIP Annual Congress. In order to continue to attract participants and to engage volunteers in Section activities, this work is contemporary and comprehensive.

A review of programmes offered at the Congress by the Board and the Sections reveals both of these traits. Evaluations by participants rate the Congress content highly. The BPP Program Committee works with the Professional Secretary to create the main Congress program and relies on input from Member Organisations as well as FIP's internal governance structure. Program themes and specific lecture areas are developed from careful thinking about the profession's directions and service provisions.

Perhaps the most ambitious Section activity occurred last year in Basel in conjunction with the Annual Congress located there. The Hospital Pharmacy Section hosted a three day Consensus Conference on the desired future for hospital pharmacy practice on a global level. With the participation of over three hundred hospital pharmacists, seventy five statements about the future of practice in hospitals around the world were developed. The latter were adopted by official country delegates representing over seventy countries. Proceedings of the Conference have been published and translated into several languages. The Section will be developing programs around this work at forthcoming Congresses and is encouraging local member organisations to utilize the Proceedings as a basis for ongoing national health workforce planning and hospital pharmacy practice development.

Working Groups

Consistent with the Strategic Plan of the Board, several Working Groups have been appointed and deliberating their points of reference. Several final reports have been produced. Specifically, the Working Group on Collaborative Practice, led by Dr. Jill Martin (USA) and Mr. David Pruce (UK) has concluded its Report and it has since then been adopted both by the BPP and the Bureau. This Report is presently serving as a reference for further dialogue with the World Health Organization and the World Health Professions Alliance.

The Working Group on Pharmacy Workforce has just presented its Final Report to the Board of Pharmaceutical Practice at its March 2009 meeting. The Working Group on Reimbursement Models for Pharmacy Practice also presented its Report at the March 2009 meeting. The Recommendations of these two Working Group are currently under consideration for further action by FIP. Both of these Reports represent significant effort to look strategically at positioning the profession to meet the needs of patients and their health care systems in making the best use of medicines.

A new Working Group on Partnering with Patients was authorized by the Board at its March, 2009 meeting. The Points of Reference are currently being finalized as is the identification and appointment of members.

Liaison Work with the Bureau

The FIP Bureau has requested that the BPP take on special liaison functions in two areas: updating the Good Pharmacy Practice Standards of FIP and reforming pharmacy education. With regard to the former, a Working Group on these revisions has been at work for the past two years. Several face to face meetings have taken place in addition to holding a consultative meeting with representatives of FIP Member Organisations and selected staff of the World Health Organization (WHO). A Reference Paper on Good Pharmacy Practice is

currently being finalised based on comments and review received from Member Organisations. The completed Reference Paper will then serve as the basis for constructing specific policy recommendations for consideration by the Council at its meeting next year in Lisbon.

Effort relating to reform of pharmacy education has been vested in the Taskforce on Pharmacy Education presently headed by Professor Ian Bates of the University of London School of Pharmacy (ULSP) and guided by an Advisory Committee representing various regions of the world. The Taskforce operates as part of a collaborative agreement between FIP and the ULSP. The Professional Secretary serves as the Liaison between the Taskforce and the Bureau. As one might imagine, the reform of pharmacy education around the world is a daunting and deep task. A variety of specific theme areas have been developed by the Taskforce and are currently being intensively defined and examined through collaborative work with the World Health Organization and the United Nations Education and Scientific Organization (UNESCO). Further reporting on these initiatives will be done by the FIP President since these efforts engage both of the Boards and the Bureau and will have far reaching organisational impacts as the work is matured.

Relationship between the Boards of Pharmaceutical Practice and Pharmaceutical Science

Included in the BPP Strategic Plan is an emphasis on Translational Science; that is, bringing the results of scientific investigation and discovery to the care of patients in a timely and efficient manner. This calls on both of FIP's boards to work collaboratively and to exchange views and information on a timely basis.

I am pleased to report that through the collaborative work of the two Board secretaries and the respective Board presidents, great strides are being made in this area of organisational activity. Joint BPP/BPS symposia at

the annual Congress are focusing on important areas such as pharmagenomics, pharmaceutical waste and environment, application of post-marketing surveillance to product safety and integrity and applications of nanotechnology to drug targeting. Planning for the Pharmaceutical Sciences World Congress in 2010 has also engaged Board of Pharmaceutical Practice input. The Professional Secretary participated in the 2008 invitation conference on Pharmaceutical Sciences 2020 and the outcomes of that conference are currently being reviewed by the BPP.

Advances in science have direct applications to the nature, scope and evolution of the profession of pharmacy and its several practice sectors. Going forward, the rapid pace of change in science will need careful review and examination by the practice community. This will be a focus for the forthcoming year.

Going Forward

Renewing the strategic and tactical directions of the BPP will be a major focus for the forthcoming year. The BPP Executive Committee is planning an all day session on this matter for October, 2009. It is time to review all of the Reports prepared by the Working groups and to harmonize these efforts with the broader FIP 2020 plan. Each of the BPP's Sections have also been requested to update their Strategic Plans with a particular emphasis on integration among the nine Section, bringing practice and science together in their areas of expertise and creating mechanisms for financial support for expanded activities of the BPP.

More information on the FIP Board of Pharmaceutical Practice and its projects can be found on the FIP website at www.fip.org

Members of the Board of Pharmaceutical Practice

- **Prof. Philip J. Schneider**
Chairman of the Board of Pharmaceutical Practice
- **Prof. Henri R. Manasse, Jr.**
FIP Professional Secretary
- **Prof. Kamal K. Midha**
FIP President
- **Mr Ton J.M. Hoek**
FIP General Secretary
- **Dr Vinod P. Shah**
FIP Scientific Secretary
- **Dr Th. F.J. Tromp**
*Member of BPP ExCo – Imm. Past Chairman BPP –
FIP Vice President*
- **Dr Régis Vaillancourt**
FIP Vice President
- **Mr Andrew Lofts Gray**
*Member of BPP ExCo/President –
FIP Hospital Pharmacy Section*
- **Ms Eeva Kirsti Teräsalmi**
*Member of BPP ExCo/Secretary –
FIP Community Pharmacy Section*
- **Dr Jennifer Lillian Marriott**
President – FIP Academic Pharmacy Section
- **Prof. Wafa Y. Dahdal**
Secretary – FIP Academic Pharmacy Section
- **Prof. Marion Schaefer**
President – FIP Administrative Pharmacy Section
- **Prof. Marina Altagracia**
Secretary – FIP Administrative Pharmacy Section
- **Dr Bernard Poggi**
President – FIP Clinical Biology Section
- **Dr Sónia Faria**
*Secretary – FIP Clinical Biology Section – Observer, YPG
Chair 2008-2009*
- **Mrs Martine Chauvé**
President – FIP Community Pharmacy Section
- **Mr Stephen J. Curtis**
Secretary – FIP Hospital Pharmacy Section

- **Dr Linda B. Hakes**
President – FIP Industrial Pharmacy Section
- **Ms Henriette Sophie Jansen, PharmD**
Secretary – FIP Industrial Pharmacy Section
- **Dr Frans van de Vaart**
President – FIP Lab. & Med. Control Serv. Section
- **Dr Antonio J. Bica**
Secretary – FIP Lab. & Med. Control Serv. Section
- **Mr Helmut G. Höhn**
President – Military & Emergency Pharmacy Section
- **Mrs Jane Dawson**
Secretary – Military & Emergency Pharmacy Section
- **Dr Alexander Nii Oto Dodoo**
*President – Pharmacy Information Section –
BPP Expert Member*
- **Ms Lindsay McClure**
Secretary – Pharmacy Information Section
- **Prof. Martin Schulz**
Chairman BPP Progr Comm/BPP Expert Member
- **Mrs Dan Mei**
BPP Expert Member
- **Ms Agathe Wehrli**
BPP Expert Member
- **Mr Dominique Jordan**
Vice President – FIP Community Pharmacy Section
- **Prof. Toby Clark**
Treasurer – FIP Hospital Pharmacy Section
- **Mr John Nguyen**
Observer IPSF President 2008-2009

The FIP Academic Section

President: Jennifer Marriott, Australia

Jennifer.Marriott@vcp.monash.edu.au

Secretary: Wafa Y. Dahdal, USA

The Academic Section seeks to explore issues of importance to pharmacists practising in academia. Issues are therefore related to teaching and learning, such as curriculum, assessment and teaching methods, etc. At each Congress, symposia are presented that explore these issues and provide a forum for discussion and sharing of ideas and experience. Newsletters are circulated to all Section members to provide information concerning topics for the Congress symposia and upcoming events of interest. Projects that have been proposed aim to improve the practice of pharmacy worldwide, increase the number of academics who are members to improve teaching and learning and therefore increase the standard of education and consequently of well-educated graduates.

Mission and vision

The goal of the Academic section is to advance the profession of pharmacy and improve the health of the community by providing high quality education to those wishing to become pharmacists and continuing professional development to working pharmacists. This is achieved by providing symposia at the annual Congress that enable academic pharmacists to remain abreast of educational developments. Projects are undertaken by the section as funds become available to assist the development of resources and to enable sharing of expertise.

Activities and accomplishments

In 2008-2009 the section worked toward its goal by presenting three topical and well-attended symposia. At each of these symposia issues were presented and discussed by those present. A number of projects were identified and debated at the annual business meeting.

Two projects were chosen to be undertaken. The first project will identify an academic in all schools of pharmacy worldwide to provide a point of communication about FIP in general and the Academic section in particular. This project aims to improve membership in the section, to increase engagement with the section programs and to increase the distribution of the section newsletter. The second project, to be conducted in conjunction with the Global Pharmacy Education Taskforce, is to develop a resource-sharing website for use and access by all academics, but more particularly those in developing countries.

The FIP Administrative Pharmacy Section

President: Marion Schaefer, Germany

schaefer@zeg-berlin.de

Secretary: Marina Altagracia Martinez, Mexico

The FIP Administrative Pharmacy Section offers a platform for members of different professional backgrounds who share an interest in the circumstances under which pharmacy is practiced worldwide. This includes social, political, economic as well as organisational aspects of pharmacy practice.

Embedded in this is a focus on medicines, their effect, their benefits and risks and their cost-effectiveness. Therefore, the section closely cooperates with the FIP Special Interest Group of Pharmacoepidemiology (within the Board of Pharmaceutical Sciences) and organises well attended sessions during the annual FIP Congresses, often as joint sessions together with other Sections.

The Administrative Pharmacy Section, currently comprising 224 members, initiates internal working groups on demand and focuses attention on one project at a time. Communication between members and between face-to-face meetings is organised through quarterly newsletters and intra-section correspondence when needed.

Mission and vision

The main interest of the section is the organisation of pharmacy practice and the provision of evidence for decision making in all areas related to drug use, pharmacy policy and advocacy. With this objective, the section has tried to analyse the conditions of pharmacies in several countries using selected parameters for the evaluation (Drug Policy Project).

Activities and accomplishments

The Section's vice president recently finalised a report entitled "Drug Policy Project" and submitted it to the Board of Pharmacy Practice. A publication of the report is planned for the near future. A new project proposal on the "International Exploration of the Status of Homeopathic Drugs: Regulatory, Clinical and Commercial Aspects" was submitted by our immediate past president and will hopefully commence in 2009.

The two main section topics of last year's annual FIP Congress in Basel were "Professional and regulatory issues of Patient Safety," and "Patient Safety, Risk Assessment and Risk Management," which prompted a lively discussion among participants. The FIP Congress in Istanbul will see the section focus on "Improving the use of medicines through Medication Management" and "Strategies of pharmacists to adapt to increased competition." All these themes are very much in line with the mission and goals of the Section.

The FIP Clinical Biology Section

President: Bernard Poggi, France

bernard.poggi@chu-lyon.fr

Secretary: Sónia Faria, Portugal

The Clinical Biology Section (CBS) consists of members who are experts in the different fields of clinical laboratory medicine, such as clinical biochemistry, immunology, biological haematology, parasitology, microbiology, molecular biology and genetics. Clinical biologists work closely with physicians in the diagnosis of diseases. The Section has also dedicated itself to the development of new biotechnology like pharmacogenomics and nanotechnologies.

Mission and vision

The main objective of CBS is “to study and maintain the development and the protection of the scientific and professional interests of all Pharmacists engaged in Clinical Biology and Laboratory Medicine” and more precisely:

- Establishing and developing exchange of information intended to benefit the coordination and improvement of the scientific and professional activities of the pharmacists engaged in Clinical Biology and Laboratory Medicine;
- Issuing recommendations /advising on disease prevention regarding patient, genetic prediction of diseases, biological follow up of diseases and therapeutics;
- Organising meetings and conferences during the FIP congresses.

Activities and accomplishments

Over the last few months, the work of the CBS has focused on the election of a new Board, adoption of new statutes and the development and implementation of a Section Strategic Plan, in accordance with BPP and FIP Strategic Plan.

At the occasion of the FIP General Assembly on 2 September 2008, members adopted new statutes for the CBS. These new statutes were needed to comply with FIP internal rules and are currently under review and validation by the FIP Executive Committee, to be ratified at the upcoming FIP Congress in Istanbul.

CBS is also expanding its presence at the FIP annual congress with plans to prepare and host a new and extensive programme on allergies in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine.

The FIP Community Pharmacy Section

President: Martine Chauvé, France

fip@pharmakon.dk

Secretary: Eeva Teräsalmi, Finland

The FIP Community Pharmacy Section (CPS) is the largest of the FIP sections with more than 2,400 members. The activities decided by the Executive Committee and the Steering Committee are implemented by the Section as well as by the "Foundation for Continuing Education Activities of the Section for Community Pharmacists of FIP," founded in 1987. The Section edits two electronic newsletters: ZOOM and Professional News.

Mission and vision

The mission of the CPS is to assist pharmacists, wherever they live and practise, in the deliverance of medicines, health products and services that will improve medicine use and advance patient care.

The vision for the Community Pharmacy Section is:

- To develop strong relationships with all pharmaceutical associations that have focus on community pharmacists and pharmacists with other primary care functions and services;
- To support pharmacists so that they can fulfill their responsibilities towards society and provide their services at a high professional level;
- To be a meeting point for pharmacists so that CPS can facilitate further development of pharmacy practice within the primary health care sector in countries all over the world.

The strategic plan of the Section has three main areas of activities: to be a resource center, to advance community pharmacy practice and to improve communications.

Activities and accomplishments

Section Statutes that had been revised in 2007 went on to be approved by the FIP Council in 2008.

A report on "The role of the pharmacists in public health" was updated in 2008, which includes a theoretical segment and all presentations related to this topic given during the Section programmes at FIP Congresses in 2005, 2006, 2007 and 2008.

CPS organised 11 sessions at the Congress in Basel, alone or in collaboration with other sections. The CPS poster award was given to three outstanding poster presentations. This award is made possible by a grant from IMS Health.

With regards to specific projects, the Section has supported a research project by Katja Hakkarainen, Finland: "Models of medication review – an international comparison." The results were presented at the FIP congress in Basel. The Section has also established a new initiative: "Quality work in pharmacies – how to develop indicators for change processes and outcomes." The main goal for the project is to follow and research the implementation strategies in pharmacies and develop suitable ways of measuring the outcomes of pharmacist actions. CPS has also supported implementation of

Good Pharmacy Practice in Jordan, an ongoing initiative supported by the FIP Foundation for Education and Research.

Recently, CPS has sent a report to FIP entitled “Liberalisation of the pharmacy sector and adaptation to changes”. Based on this report, FIP has invited the Section to draft the programme for the Leadership Conference at the FIP Congress in Istanbul, 2009.

The FIP Hospital Pharmacy Section

President: Andy Gray, South Africa

graya1@ukzn.ac.za

Secretary: Stephen J Curtis, UK

The Hospital Pharmacy Section (HPS) seeks to represent hospital pharmacists from around the world. This is the third largest Section of FIP and was founded in 1957. At present, in addition to representation through member organisations of the FIP, the Section has 440 individual members. The overall intent of the Section is to focus on education, communication and improving the practice of pharmacy in hospitals around the world.

Mission and vision

The mission and goals of the Section are aligned with those of the FIP's 2020 Vision. Specifically, the Section seeks to enhance pharmacy practice by identifying ways in which pharmacists in hospital practice can best be employed to achieve effective medicines distribution and supply-chain management, provide effective pharmaceutical care and improve prescribing practices. Other strategic issues being addressed are the development of better financial models, evidence-based practice, assuring competency and a sufficient pharmacy workforce.

Activities and accomplishments

In order to shape this strategic approach, the HPS hosted an extremely well-attended and productive Global Conference on the Future of Hospital Pharmacy on 30 and 31 August 2008 in Basel, Switzerland. The event was attended by 348 registrants, representing 98 different nations. This was the most globally representative hospital pharmacy event ever held. The funding raised from a variety of sponsors allowed HPS to fully sponsor 20 participants from developing countries. Highlights of the event included the presentation of the results of the Survey of Global Hospital Pharmacy Practice (which elicited responses from 44% of all countries recognized by the United Nations, representing 82.9% of the world's population), the presentation of 6 commissioned evidence summaries, covering all areas of the medicine use process in hospitals (procurement of medicines, preparation and distribution, prescribing, administration of medicines, monitoring of patient outcomes, as well as issues related to human resources and training) and the development of 75 consensus statements – the Basel Statements on the Future of Hospital Pharmacy.

All of this material was published in a March 2009 special supplement of the American Journal of Health-System Pharmacy, which can be accessed at http://www.ajhp.org/content/vol66/5_Supplement_3/index.dtl.

The process of disseminating, popularising and implementing the Basel Statements has now begun, with activities in every region of the world. A policy to guide translation of the Basel Statements has been developed. Two Chinese translations have been completed and a French translation is underway. Translation into Spanish is also planned in the near future.

The support of all FIP member organisations, the regional pharmaceutical fora and individual hospital pharmacists will be key to the success of this venture. In order to more closely align its organisational structure to that of the World Health Organization, the HPS has

co-opted a representative from the Eastern Mediterranean region onto the HPS Board of Officers. This will allow an HPS Vice-President to interact closely with each of the 6 WHO regions. This entire effort depends on clear communications, using every tool at the Section's disposal: the FIP website, the FIP-HPS listserv, as well as electronic newsletters. Sessions to specifically advance this agenda have also been planned for the FIP Congress in Istanbul.

This past year has been a busy but productive time for the HPS. An agenda for action has been set and is being driven forward with enthusiasm.

The FIP Industrial Pharmacy Section

President: Linda Hakes, Germany

Linda.Hakes@ucb-group.com

Secretary: Henriette Jansen, Germany

Founded in 1955, FIP's Industrial Pharmacy Section has expanded to a worldwide industrial pharmacy network with many activities. IPS strives to spread its activities across different regions, involving both participants and organisations from developing and developed countries. IPS has a special focus on young pharmacists and students and encourages their interest in the pharmaceutical industry. IPS is among the top three largest sections within FIP, with 486 members.

Currently, IPS activities have an emphasis on the quality of medicines. However, other topics such as clinical trials, pharmacy education and orphan drugs have been the subject of recent events. To this end IPS frequently cooperates with other sections in the BPP; with special interest groups in the BPS; and with outside parties including national and (supra-) regional industry associations, scientific and professional societies (e.g. ISPE, AAPS, RPSGB, EUFEPS), and health regulatory agencies and inspectorates (EMEA, FDA).

Mission and vision

The mission of the Industrial Pharmacy Section is to represent and serve the pharmaceutical profession and pharmaceutical sciences within the pharmaceutical industry worldwide.

Activities and accomplishments

IPS has maintained its member benefit plan, consisting of reduced fees to IPS sponsored events, subscription to the quarterly IPS Newsletter (full colour), and subscription to the journal Industrial Pharmacy. Prof. M.H. Anisfeld has been actively involved on behalf of IPS in the Pharma-Bridge Project.

Furthermore, IPS has presented at various conferences worldwide, thereby promoting FIP. In July Dr. A.P. Sam and Dr. L.B. Hakes gave presentations on Quality by Design and PAT at the SAAPI Conference in South Africa. In September the Quality by Design Workshop in Antalya, Turkey took place with Dr. M. Khan (FDA) and in October a Workshop on Paediatric Medicines was held in The Netherlands, where on both occasions Dr. A.P. Sam presented on behalf of IPS. In December, Dr. L.B. Hakes gave a lecture on continuing education for industrial pharmacists at the Egyptian Pharmaceutical Conference.

Two IPS Awards were granted during the FIP Basel Congress. The IPS Medal Award was given to Prof. Dr. Terezinha Pinto from Brazil, to recognize her outstanding contribution to pharmaceutical science and practice within industry. The Mike How Award was given to Mr. Luther Gwaza from Zambia, to recognize and stimulate his keen interest and passion for the Industrial Pharmacy sector.

The FIP Laboratories and Medicines Control Section

President: Frans van der Vaart, The Netherlands

f.j.van.de.vaart@winap.nl

Secretary: Antonio Bica, Portugal

The Laboratory and Medicinal Control Section (LMCS) was officially formed in 1980 at the Madrid FIP Congress, previously having been a committee for more than 60 years. The scope of the section is the quality assurance of medicinal products in the broadest sense: laws and rules governing admission to the market as well as quality control of products currently available on the market, or prepared by pharmacists for their patients.

This year the LMCS had 55 members and working relationships with about 50 laboratories.

Mission and vision

The mission of the section is to undertake and coordinate the research and development of methods, to establish principles for assuring the quality of pharmaceutical and medical products both nationally and internationally and to exchange information and opinions upon technical and professional issues pertaining to medicines control and quality assurance.

Activities and accomplishments

LMCS organised a successful symposium on biosimilars as part of a full day symposium with the Board of Pharmaceutical Sciences at the 2008 Annual Congress in Basel. The focus was on how to deal with biosimilars in daily practice, taking responsibility for patient safety as well as for efficient use of health care budget.

This past year the 10th round of the LMCS Proficiency Testing Program was successfully completed. Fifty laboratories participated: 20 from Europe, 16 from Asia, nine from Africa, four from the Americas and one from

Australia. Each lab received a box with three samples.

The 2008 program covered:

- Assay of iodine in alcoholic iodine solution;
- pH measurement of a buffer solution;
- Melting point measurement of a raw material.

Reports indicate that the assay of iodine appeared to be difficult: only two-thirds of all participants were able to report a result that was within 3% of the correct value. One-third were outside those limits, mostly on the low side. For the pH measurement more than 90% of the participants were within 0.1 of the correct value. Also for the melting point measurement the results were good, more than 90% were within 3% of the correct value.

The 2009 round has started, results will be available in Istanbul. Also, a symposium on possibilities and limitations for quality control of biotech products will be organised for the 2009 FIP Congress in Istanbul.

The FIP Military and Emergency Pharmacy Section

President: Col. Helmut G. Höhn, Germany

HelmutHoehn@bmvg.bund.de

Secretary: Mrs Jane Dawson, New Zealand

The aim of the Military and Emergency Pharmacy Section (MEPS) is to establish close co-operation between military pharmaceutical services and other organisations that provide pharmaceutical services in a humanitarian aid or emergency relief situation. The members have as their mission the study of problems relating to the provision of these services in a difficult environment on an international basis and to co-ordinate pharmaceutical services in general. MEPS is a small section with 78 active members. For its size MEPS is an active section, with quarterly newsletters, email correspondence and updates, diverse activities at the annual Congress and participation in two significant special projects.

Mission and vision

The members of MEPS have a very specific niche in pharmacy that encompasses many of the roles detailed in other sections. What is different for the MEPS pharmacist is the difficulties associated with working with the multiplicity of roles undertaken by a single individual in such diverse areas as in emergency situations, humanitarian aid situations, logistics as well as routine provision of healthcare, education and patient communication.

The MEPS strategic plan attempts to address some of the issues that arise in emergency practice. In particular the plan focuses on:

- Raising professional standards through the special projects, problem sharing, and the commencement of a new initiative to develop some practice guidelines;
- Development of strategies related to the safe use of medicines by providing tools to improve communication (Pictogram/Asthma projects); and
- Encouraging research. As an example, the first new practice guideline is about the use of evidence based medicine in selection of product for the emergency environment.

Activities and accomplishments

The two special projects (Pictogram/Asthma projects) continue to advance the standard of practice in the MEPS environment. These projects are of great pride and accomplishment to the section and have made great strides in advancing patient understanding of medicines use. Full reports of both projects may be found on the FIP website. The other highlight is as always, the annual educational visit to the host nation during the FIP Congress. In 2008 this involved a visit to the Swiss Armed Forces.

The FIP Pharmacy Information Section

President: Alexander Dodoo, Ghana

alexooo@yahoo.com

Secretary: Lindsay McClure, UK

Currently serving 300 members from more than 70 countries, the FIP Pharmacy Information Section aims to promote networking between pharmacists who provide information services and the key role of medicines information programmes in supporting clinical practice and enhancing public health.

Mission and vision

The Pharmacy Information Section organises a wide range of programming at the annual FIP Congress each year and, through the use of a network of thematic working groups, develops and promotes new initiatives relating to drug and health information. A key emerging interest area is health informatics with a growing role for pharmacists around the world in health information technology initiatives such as the electronic transmission of prescriptions and shared electronic patient health records.

Members are kept in close contact with the Section's activities through a members only email list, the members only section on the FIP website and the section's popular quarterly newsletter, Info-Link. During the annual FIP Congress, the section provides a range of networking opportunities including varied section programming, a poster session, a formal dinner and a well-attended business meeting where members can provide their views on the section's strategic direction. In 2008, the section financially supported pharmacists from Nepal and Nigeria to attend the Congress through the Section's stipend programme.

Activities and accomplishments

A key success for the Section in the past year was the FIP Council's adoption of two policy statements developed by the section's working groups on 'Medicines Information for Patients' and 'Antimicrobial Resistance'.

Current initiatives include a review of an educational booklet on patient counseling which was developed in partnership with FIP and the International Pharmaceutical Students Federation (IPSF), and the organisation of a workshop on 'Developing Medicine Information Services' which will precede the 2009 FIP Congress in Istanbul. The workshop aims to provide continuing education to pharmacists responsible for providing, developing or supporting medicines information services – ranging from pharmacists who specialise in medicines information to those responsible for maintaining and using information resources for clinical practice. The focus is on enhancing services in regions with limited access to objective analysis and clinical information support.



growth

fip young pharmacist group (ypg)

The 2008-09 Steering Committee was elected during the 2008 FIP Congress Basel, Switzerland:

Chair: Sónia Faria, Portugal Sónia, soniafaria@labamaro.pt

Project Coordinator: Zhining Goh, Singapore

Public Relations Officer: Cairo Toledano, Mexico

The YPG represents pharmacy practitioners and scientists, members of FIP who, because of their age and/or status as recent graduates, occupy a specific niche in the profession. The mission of the YPG is to help develop individuals who can act as agents of positive change at local, national and international levels, both in the profession and in society. It acts as a member-to-member gateway to FIP activities, creating opportunities by exchange of information.

YPG comprises FIP individual members coming from the Board of Pharmacy Practice Sections and Board of Pharmaceutical Sciences Special Interest Groups. In December 2008, YPG counted 520 individual members with an increase of approximately 10% after the last FIP congress in Basel.

Mission and vision

YPG welcomes and encourages:

- Practitioners, scientists, researchers, academics and members from all disciplines;
- Innovative ideas and a professional forum for young people;
- Active participation in the FIP bodies and projects;
- Guidance for new FIP members;
- Support for innovative projects through the FIP foundation;
- A dynamic educational and social programme at the FIP Congress especially for young pharmacists;
- Facilitated incorporation into an international organisation, easing the transition from pharmacy student to professional pharmacist involvement.

In the future YPG expects to find new ways to reach our members and to increase our number of members, which will in consequence increase the number of members of FIP Sections/SIG's. To be able to achieve this goal we are planning to:

- Bring young pharmacists representing the member organisations of FIP with YP groups;
- Develop a project concerning Pharmacy Profession forming international teams of young pharmacists;
- Find inside our group interested young pharmacists coming from different regions in order to facilitate the contact within these regions.

We also expect to encourage the FIP member organisations to create and/or support the development of specific networks for young pharmacists. These structures allow an approach of young pharmacists recent graduates that expect a smooth integration in their future profession.

The FIP Young Pharmacists Group foresees this strategy as a way to find the new leaders of tomorrow and an integration of the future experts of our profession inside the professional organisations bringing them a new dynamic. These professionals represent the future of our profession and are the leaders of tomorrow.

Activities and accomplishments

At the 2008 FIP Congress in Istanbul the topic for the 2008 YPG Educational Forum, a unique event hosted by YPG, was "The role of pharmacists in primary health care". This forum debated the barriers and facilitators faced by pharmacists in the developing world and the importance of primary health care. At the upcoming 2009 FIP Congress in Istanbul the YPG and the Educational Forum will delve into the issue of "**Pharmacy practice in the era of pharmacogenomics – Are we ready for the prime time?**". This forum will debate the ethical, legal, social, and policy issues that pharmacy will confront in coming years by developments in pharmacogenomics.

The YPG maintains three major routes of communication with members: a members-only e-list, and an e-group open to both members and nonmembers. By spring 2009, the e-list facilitated communication with our 500+ members and the e-group connected 1000+ pharmacists worldwide.

We also expect to increase our communication using the FIP website Members Only area. The new area will include new communication tools that can be effectively used to reach our members in an innovative way.

Young Pharmacists/ Pharmaceutical Scientist Grant for Professional Innovation

FIP members from Australia, India, Nigeria, Pakistan, Peru, Portugal, Puerto Rico, Switzerland and Zimbabwe answered to the 2008 Young Pharmacists/Pharmaceutical Scientist Grant for professional innovation call for applications. The 2008 grant recipient is Mr. Luther Gwaza, from Zimbabwe. The title of his research is "African Potato and ARVs: Evaluating the effect of African Potato (hypoxis obtuse) on drug metabolism in healthy volunteers". Luther described how the lack of scientific information on herb-drug interactions creates major problems of therapeutic failure, resistance and/or toxicity with antiretroviral drugs considering that the majority of HIV positive people in Zimbabwe use herbal medicines. The Board of Directors of the FIP Foundation for Education and Research supported and presented the award.

Answering the 2009 call for applications, grant proposals were received from Australia, India and Peru. We are still receiving the last applications sent to the FIP foundation. The winner would be announced and presented in September 2009 at Istanbul Congress.

Mike How Award for Young Professionals and Pharmacy Students

The FIP Industrial Pharmacy Section, International Pharmaceutical Students' Federation and YPG Mike How Award for Young Professionals and Pharmacy Students was presented for the first time during the 67th FIP Congress in Beijing, to support individuals involved in the development, manufacturing and regulatory aspects of Pharmaceuticals. Last year the winner was also Mr. Luther Gwaza, from Zimbabwe. Mr. Gwaza is a Senior Regulatory Officer with the Pharmacovigilance and Clinical trials unit, Medicines Control Authority of Zimbabwe (MCAZ), the national drug regulatory agency in Zimbabwe. Luther is also an assistant lecturer of Pharmaceutics with the School of Pharmacy, University of Zimbabwe.



resources

BALANCE SHEET AT DECEMBER 31st, 2008

After appropriation of the result for 2008 – Expressed in EUR

		December 31 2008	December 31 2007
FIXED ASSETS	1	686 760	690 888
CURRENT ASSETS			
Debtors, prepayments and accrued income	2	280 407	387 859
Cash at bank and in hand	3	1 982 575	2 279 232
TOTAL CURRENT ASSETS		1 982 575	2 279 232
TOTAL ASSETS		1 982 575	2 279 232
CAPITAL AND RESERVES			
Capital	4	1 525 971	1 540 795
Congress reserve	4	453 780	453 780
Board of Pharmaceutical Practice reserve	5	32 174	32 418
Board of Pharmaceutical Sciences reserve	5	234 868	378 049
Regional Forums Reserve	6	46 049	55 846
Reserve Centennial	6	200 000	100 000
Reserve HIV/AIDS	6	10 000	-
Reserve Pharmacy Education Taskforce	6	-	40 000
Total Capital and Reserves		2 502 843	2 600 888
PROVISIONS	7	9 113	91 812
CURRENT LIABILITIES	8	437 787	665 280
TOTAL CAPITAL AND RESERVES AND LIABILITIES		2 949 742	3 357 979

INCOME

Membership fees	9
FIP World Congress revenues	10
HPS Global Conference revenues	10
PSWC Congress revenues	10
Publications	11
Other income BPP	19
Other income BPS	20
Sections income	23/24
WHO/Impact income	
Other income	12

TOTAL INCOME**EXPENSES**

Personnel costs	13
Office costs	14
Meeting costs	14
Travel expenses Ext. Representation	14
Website and IT-costs	
Depreciation of fixed assets	1
Special Projects (incl. Reg. Forums & PET)	15
Direct FIP World congress costs	16
HPS Global Conference costs	16
PSWC Congress costs	16
Publications	17
Subventions	18
Expenses BPP	19
Expenses BPS	20
Sections costs	23/24
Maintenance Fund	7
WHO/Impact expenses	
Other expenses	23

TOTAL EXPENSES

STATEMENT OF INCOME AND EXPENDITURE FOR THE YEAR 2008

After appropriation of the result for 2008 – Expressed in EUR

Actuals 2008	Budget 2008
843 571	860 000
1 642 183	1 440 000
464 883	600 000
-	-
14 948	5 000
6 986	-
8 250	-
178 504	120 000
92 246	-
60 712	5 000
3 312 283	3 030 000

Budget vs actuals	Actuals 2007
(16 429)	851 808
202 183	1 543 017
(135 117)	-
-	1 442 428
9 948	2 202
6 986	-
8 250	3 094
58 504	180 914
92 246	-
55 712	19 604
282 283	4 043 067

845 283	750 000
200 485	215 000
141 613	145 000
94 775	35 000
186 674	55 000
25 479	25 000
102 697	40 000
854 072	814 500
353 047	600 000
-	-
101 021	60 000
8 500	8 500
108 575	102 000
200 086	50 000
178 806	120 000
3 151	10 000
92 246	-
-	5 000
3 496 510	3 035 000

95 283	689 143
(14 515)	178 197
(3 387)	147 395
59 775	80 157
131 674	44 995
479	19 054
62 697	26 423
39 572	971 811
(246 953)	-
-	1 047 808
41 021	61 569
-	28 500
6 575	118 430
150 086	62 279
58 806	183 150
(6 849)	10 000
92 246	-
(5 000)	-
461 510	3 677 911

OPERATING RESULT

Financial result

21

NET RESULT BEFORE APPROPRIATION

Appropriation of the result, (from)/to:

BPP General Reserves	5
BPS General Reserves	5
BPS General Reserves (PSWC profit)	5
Regional forums reserve	6
Reserve Centennial	6
Reserve Taskforce on Education	6
Reserve HIV/AIDS	6
Section Capital	4
FIP Capital	4

TOTAL APPROPRIATED

(184 227)	(5 000)
86 182	5 000

(179 227)	365 156
81 182	(59 592)

(98 045)	-
----------	---

(98 045)	305 564
----------	---------

(244)	
(143 181)	
-	
(9 797)	
100 000	
(40 000)	
10 000	
(302)	
(14 522)	

	(17 085)
	(10 530)
	208 310
	(15 774)
	100 000
	40 000
	-
	(2 236)
	2 879

(98 045)	-
----------	---

(98 045)	305 564
----------	---------



*realising the vision
through fip members*



IDA
Pharmacy Technician

Pharmacy Technician



801

802

803

806

807

808

811

812

813

816

817

818

821

822

823



जश

आरोग्य हाच आमचा ध्यास

मेडिकल अँड

PATIENT COUNSELLING AREA
रुग्ण सल्लागार क्षेत्र

बै
घ
ना
थ

दवाँ















INSTRUMENTS
BAIGNOIRS
DENTIFRICES
COLLYRES

Apaisem
CALME



HYALURON
Sérum en un clic d'usage
HYALURON OPTIC
PROTECTEUR
HYDRATANT
ANTI-ROUGEUR

ACTYANE
ACTYANE
L'UNIQUE EXCEPTIONNELLE
1 tube : 17€50
3 tubes : 19€50












FACS














Anno 1796

Kruiden.

Drogist







CRO49
CROMATOGRAFO
HPLC



LaChrom

LaChrom

LaChrom

LaChrom

LaChrom

annual report colophon

Federation Internationale Pharmaceutique (FIP)

PO Box 84200

2508 AE

The Hague, The Netherlands

www.fip.org

Art Direction/Design

United 135, The Netherlands

Karim Cherif, Lian Aelmans

www.united135.com

Printing

Koninklijke De Swart

www.kds.nl

Paper

Cover: ON Offset 300gr.

Inside: ON Offset 100gr.

Special thanks to Lomography

www.lomography.com

Special thanks to all the FIP Member Organisations who contributed photos to the 2008-2009 Annual Report:

- Canadian Pharmaceutical Federation
- Colegio Nacional de Químicos Farmacéuticos de Colombia
- Conseil National de l'Ordre des Pharmaciens
- Finnish Pharmacists Association
- Indian Pharmaceutical Federation
- Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie
- Pharmaceutical Society of Australia
- Turkish Pharmacists Association



Federation Internationale Pharmaceutique (FIP)